context stringlengths 21 33.9k | category stringclasses 2
values | entity stringlengths 1 12 | entity_type stringclasses 5
values | query stringlengths 97 3.31k | answer stringlengths 12 169 |
|---|---|---|---|---|---|
On the Closing Date, the Borrower and lender entered into a Loan Agreement (as it may be amended from time to time, the “Loan Agreement”) providing for the Credit Facility, and the Guarantor executed a Guaranty Agreement providing for its guarantee of the payment and performance of the obligations under the Loan Agreement. On March 31, 2023, the Company entered into Amendment No. 5 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit to up to $ 150.0 million, adjusted the interest rate and fee charged on the credit facility and extended the expiration date of resolving credit note to March 29, 2024. On March 28, 2024, the Company entered into Amendment No. 6 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit up to $ 10.0 million and extended the expiration date of the revolving credit note to March 31, 2025. The Credit Facility bears interest at a rate of the sum of The Secured Overnight Financing Rate (SOFR) plus 125 basis points ( 1.25 %) or the highest of the Prime Rate, the sum of the Overnight Bank Funding Rate plus 50 basis points ( 0.50 %) and the sum of Daily Simple SOFR plus 100 basis points ( 1.00 %). | text | 150.0 | monetaryItemType | text: <entity> 150.0 </entity> <entity type> monetaryItemType </entity type> <context> On the Closing Date, the Borrower and lender entered into a Loan Agreement (as it may be amended from time to time, the “Loan Agreement”) providing for the Credit Facility, and the Guarantor executed a Guaranty Agreement providing for its guarantee of the payment and performance of the obligations under the Loan Agreement. On March 31, 2023, the Company entered into Amendment No. 5 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit to up to $ 150.0 million, adjusted the interest rate and fee charged on the credit facility and extended the expiration date of resolving credit note to March 29, 2024. On March 28, 2024, the Company entered into Amendment No. 6 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit up to $ 10.0 million and extended the expiration date of the revolving credit note to March 31, 2025. The Credit Facility bears interest at a rate of the sum of The Secured Overnight Financing Rate (SOFR) plus 125 basis points ( 1.25 %) or the highest of the Prime Rate, the sum of the Overnight Bank Funding Rate plus 50 basis points ( 0.50 %) and the sum of Daily Simple SOFR plus 100 basis points ( 1.00 %). </context> | us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity |
On the Closing Date, the Borrower and lender entered into a Loan Agreement (as it may be amended from time to time, the “Loan Agreement”) providing for the Credit Facility, and the Guarantor executed a Guaranty Agreement providing for its guarantee of the payment and performance of the obligations under the Loan Agreement. On March 31, 2023, the Company entered into Amendment No. 5 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit to up to $ 150.0 million, adjusted the interest rate and fee charged on the credit facility and extended the expiration date of resolving credit note to March 29, 2024. On March 28, 2024, the Company entered into Amendment No. 6 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit up to $ 10.0 million and extended the expiration date of the revolving credit note to March 31, 2025. The Credit Facility bears interest at a rate of the sum of The Secured Overnight Financing Rate (SOFR) plus 125 basis points ( 1.25 %) or the highest of the Prime Rate, the sum of the Overnight Bank Funding Rate plus 50 basis points ( 0.50 %) and the sum of Daily Simple SOFR plus 100 basis points ( 1.00 %). | text | 10.0 | monetaryItemType | text: <entity> 10.0 </entity> <entity type> monetaryItemType </entity type> <context> On the Closing Date, the Borrower and lender entered into a Loan Agreement (as it may be amended from time to time, the “Loan Agreement”) providing for the Credit Facility, and the Guarantor executed a Guaranty Agreement providing for its guarantee of the payment and performance of the obligations under the Loan Agreement. On March 31, 2023, the Company entered into Amendment No. 5 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit to up to $ 150.0 million, adjusted the interest rate and fee charged on the credit facility and extended the expiration date of resolving credit note to March 29, 2024. On March 28, 2024, the Company entered into Amendment No. 6 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit up to $ 10.0 million and extended the expiration date of the revolving credit note to March 31, 2025. The Credit Facility bears interest at a rate of the sum of The Secured Overnight Financing Rate (SOFR) plus 125 basis points ( 1.25 %) or the highest of the Prime Rate, the sum of the Overnight Bank Funding Rate plus 50 basis points ( 0.50 %) and the sum of Daily Simple SOFR plus 100 basis points ( 1.00 %). </context> | us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity |
On the Closing Date, the Borrower and lender entered into a Loan Agreement (as it may be amended from time to time, the “Loan Agreement”) providing for the Credit Facility, and the Guarantor executed a Guaranty Agreement providing for its guarantee of the payment and performance of the obligations under the Loan Agreement. On March 31, 2023, the Company entered into Amendment No. 5 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit to up to $ 150.0 million, adjusted the interest rate and fee charged on the credit facility and extended the expiration date of resolving credit note to March 29, 2024. On March 28, 2024, the Company entered into Amendment No. 6 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit up to $ 10.0 million and extended the expiration date of the revolving credit note to March 31, 2025. The Credit Facility bears interest at a rate of the sum of The Secured Overnight Financing Rate (SOFR) plus 125 basis points ( 1.25 %) or the highest of the Prime Rate, the sum of the Overnight Bank Funding Rate plus 50 basis points ( 0.50 %) and the sum of Daily Simple SOFR plus 100 basis points ( 1.00 %). | text | 125 | percentItemType | text: <entity> 125 </entity> <entity type> percentItemType </entity type> <context> On the Closing Date, the Borrower and lender entered into a Loan Agreement (as it may be amended from time to time, the “Loan Agreement”) providing for the Credit Facility, and the Guarantor executed a Guaranty Agreement providing for its guarantee of the payment and performance of the obligations under the Loan Agreement. On March 31, 2023, the Company entered into Amendment No. 5 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit to up to $ 150.0 million, adjusted the interest rate and fee charged on the credit facility and extended the expiration date of resolving credit note to March 29, 2024. On March 28, 2024, the Company entered into Amendment No. 6 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit up to $ 10.0 million and extended the expiration date of the revolving credit note to March 31, 2025. The Credit Facility bears interest at a rate of the sum of The Secured Overnight Financing Rate (SOFR) plus 125 basis points ( 1.25 %) or the highest of the Prime Rate, the sum of the Overnight Bank Funding Rate plus 50 basis points ( 0.50 %) and the sum of Daily Simple SOFR plus 100 basis points ( 1.00 %). </context> | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
On the Closing Date, the Borrower and lender entered into a Loan Agreement (as it may be amended from time to time, the “Loan Agreement”) providing for the Credit Facility, and the Guarantor executed a Guaranty Agreement providing for its guarantee of the payment and performance of the obligations under the Loan Agreement. On March 31, 2023, the Company entered into Amendment No. 5 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit to up to $ 150.0 million, adjusted the interest rate and fee charged on the credit facility and extended the expiration date of resolving credit note to March 29, 2024. On March 28, 2024, the Company entered into Amendment No. 6 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit up to $ 10.0 million and extended the expiration date of the revolving credit note to March 31, 2025. The Credit Facility bears interest at a rate of the sum of The Secured Overnight Financing Rate (SOFR) plus 125 basis points ( 1.25 %) or the highest of the Prime Rate, the sum of the Overnight Bank Funding Rate plus 50 basis points ( 0.50 %) and the sum of Daily Simple SOFR plus 100 basis points ( 1.00 %). | text | 1.25 | percentItemType | text: <entity> 1.25 </entity> <entity type> percentItemType </entity type> <context> On the Closing Date, the Borrower and lender entered into a Loan Agreement (as it may be amended from time to time, the “Loan Agreement”) providing for the Credit Facility, and the Guarantor executed a Guaranty Agreement providing for its guarantee of the payment and performance of the obligations under the Loan Agreement. On March 31, 2023, the Company entered into Amendment No. 5 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit to up to $ 150.0 million, adjusted the interest rate and fee charged on the credit facility and extended the expiration date of resolving credit note to March 29, 2024. On March 28, 2024, the Company entered into Amendment No. 6 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit up to $ 10.0 million and extended the expiration date of the revolving credit note to March 31, 2025. The Credit Facility bears interest at a rate of the sum of The Secured Overnight Financing Rate (SOFR) plus 125 basis points ( 1.25 %) or the highest of the Prime Rate, the sum of the Overnight Bank Funding Rate plus 50 basis points ( 0.50 %) and the sum of Daily Simple SOFR plus 100 basis points ( 1.00 %). </context> | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
On the Closing Date, the Borrower and lender entered into a Loan Agreement (as it may be amended from time to time, the “Loan Agreement”) providing for the Credit Facility, and the Guarantor executed a Guaranty Agreement providing for its guarantee of the payment and performance of the obligations under the Loan Agreement. On March 31, 2023, the Company entered into Amendment No. 5 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit to up to $ 150.0 million, adjusted the interest rate and fee charged on the credit facility and extended the expiration date of resolving credit note to March 29, 2024. On March 28, 2024, the Company entered into Amendment No. 6 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit up to $ 10.0 million and extended the expiration date of the revolving credit note to March 31, 2025. The Credit Facility bears interest at a rate of the sum of The Secured Overnight Financing Rate (SOFR) plus 125 basis points ( 1.25 %) or the highest of the Prime Rate, the sum of the Overnight Bank Funding Rate plus 50 basis points ( 0.50 %) and the sum of Daily Simple SOFR plus 100 basis points ( 1.00 %). | text | 50 | percentItemType | text: <entity> 50 </entity> <entity type> percentItemType </entity type> <context> On the Closing Date, the Borrower and lender entered into a Loan Agreement (as it may be amended from time to time, the “Loan Agreement”) providing for the Credit Facility, and the Guarantor executed a Guaranty Agreement providing for its guarantee of the payment and performance of the obligations under the Loan Agreement. On March 31, 2023, the Company entered into Amendment No. 5 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit to up to $ 150.0 million, adjusted the interest rate and fee charged on the credit facility and extended the expiration date of resolving credit note to March 29, 2024. On March 28, 2024, the Company entered into Amendment No. 6 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit up to $ 10.0 million and extended the expiration date of the revolving credit note to March 31, 2025. The Credit Facility bears interest at a rate of the sum of The Secured Overnight Financing Rate (SOFR) plus 125 basis points ( 1.25 %) or the highest of the Prime Rate, the sum of the Overnight Bank Funding Rate plus 50 basis points ( 0.50 %) and the sum of Daily Simple SOFR plus 100 basis points ( 1.00 %). </context> | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
On the Closing Date, the Borrower and lender entered into a Loan Agreement (as it may be amended from time to time, the “Loan Agreement”) providing for the Credit Facility, and the Guarantor executed a Guaranty Agreement providing for its guarantee of the payment and performance of the obligations under the Loan Agreement. On March 31, 2023, the Company entered into Amendment No. 5 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit to up to $ 150.0 million, adjusted the interest rate and fee charged on the credit facility and extended the expiration date of resolving credit note to March 29, 2024. On March 28, 2024, the Company entered into Amendment No. 6 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit up to $ 10.0 million and extended the expiration date of the revolving credit note to March 31, 2025. The Credit Facility bears interest at a rate of the sum of The Secured Overnight Financing Rate (SOFR) plus 125 basis points ( 1.25 %) or the highest of the Prime Rate, the sum of the Overnight Bank Funding Rate plus 50 basis points ( 0.50 %) and the sum of Daily Simple SOFR plus 100 basis points ( 1.00 %). | text | 0.50 | percentItemType | text: <entity> 0.50 </entity> <entity type> percentItemType </entity type> <context> On the Closing Date, the Borrower and lender entered into a Loan Agreement (as it may be amended from time to time, the “Loan Agreement”) providing for the Credit Facility, and the Guarantor executed a Guaranty Agreement providing for its guarantee of the payment and performance of the obligations under the Loan Agreement. On March 31, 2023, the Company entered into Amendment No. 5 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit to up to $ 150.0 million, adjusted the interest rate and fee charged on the credit facility and extended the expiration date of resolving credit note to March 29, 2024. On March 28, 2024, the Company entered into Amendment No. 6 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit up to $ 10.0 million and extended the expiration date of the revolving credit note to March 31, 2025. The Credit Facility bears interest at a rate of the sum of The Secured Overnight Financing Rate (SOFR) plus 125 basis points ( 1.25 %) or the highest of the Prime Rate, the sum of the Overnight Bank Funding Rate plus 50 basis points ( 0.50 %) and the sum of Daily Simple SOFR plus 100 basis points ( 1.00 %). </context> | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
On the Closing Date, the Borrower and lender entered into a Loan Agreement (as it may be amended from time to time, the “Loan Agreement”) providing for the Credit Facility, and the Guarantor executed a Guaranty Agreement providing for its guarantee of the payment and performance of the obligations under the Loan Agreement. On March 31, 2023, the Company entered into Amendment No. 5 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit to up to $ 150.0 million, adjusted the interest rate and fee charged on the credit facility and extended the expiration date of resolving credit note to March 29, 2024. On March 28, 2024, the Company entered into Amendment No. 6 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit up to $ 10.0 million and extended the expiration date of the revolving credit note to March 31, 2025. The Credit Facility bears interest at a rate of the sum of The Secured Overnight Financing Rate (SOFR) plus 125 basis points ( 1.25 %) or the highest of the Prime Rate, the sum of the Overnight Bank Funding Rate plus 50 basis points ( 0.50 %) and the sum of Daily Simple SOFR plus 100 basis points ( 1.00 %). | text | 100 | percentItemType | text: <entity> 100 </entity> <entity type> percentItemType </entity type> <context> On the Closing Date, the Borrower and lender entered into a Loan Agreement (as it may be amended from time to time, the “Loan Agreement”) providing for the Credit Facility, and the Guarantor executed a Guaranty Agreement providing for its guarantee of the payment and performance of the obligations under the Loan Agreement. On March 31, 2023, the Company entered into Amendment No. 5 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit to up to $ 150.0 million, adjusted the interest rate and fee charged on the credit facility and extended the expiration date of resolving credit note to March 29, 2024. On March 28, 2024, the Company entered into Amendment No. 6 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit up to $ 10.0 million and extended the expiration date of the revolving credit note to March 31, 2025. The Credit Facility bears interest at a rate of the sum of The Secured Overnight Financing Rate (SOFR) plus 125 basis points ( 1.25 %) or the highest of the Prime Rate, the sum of the Overnight Bank Funding Rate plus 50 basis points ( 0.50 %) and the sum of Daily Simple SOFR plus 100 basis points ( 1.00 %). </context> | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
On the Closing Date, the Borrower and lender entered into a Loan Agreement (as it may be amended from time to time, the “Loan Agreement”) providing for the Credit Facility, and the Guarantor executed a Guaranty Agreement providing for its guarantee of the payment and performance of the obligations under the Loan Agreement. On March 31, 2023, the Company entered into Amendment No. 5 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit to up to $ 150.0 million, adjusted the interest rate and fee charged on the credit facility and extended the expiration date of resolving credit note to March 29, 2024. On March 28, 2024, the Company entered into Amendment No. 6 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit up to $ 10.0 million and extended the expiration date of the revolving credit note to March 31, 2025. The Credit Facility bears interest at a rate of the sum of The Secured Overnight Financing Rate (SOFR) plus 125 basis points ( 1.25 %) or the highest of the Prime Rate, the sum of the Overnight Bank Funding Rate plus 50 basis points ( 0.50 %) and the sum of Daily Simple SOFR plus 100 basis points ( 1.00 %). | text | 1.00 | percentItemType | text: <entity> 1.00 </entity> <entity type> percentItemType </entity type> <context> On the Closing Date, the Borrower and lender entered into a Loan Agreement (as it may be amended from time to time, the “Loan Agreement”) providing for the Credit Facility, and the Guarantor executed a Guaranty Agreement providing for its guarantee of the payment and performance of the obligations under the Loan Agreement. On March 31, 2023, the Company entered into Amendment No. 5 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit to up to $ 150.0 million, adjusted the interest rate and fee charged on the credit facility and extended the expiration date of resolving credit note to March 29, 2024. On March 28, 2024, the Company entered into Amendment No. 6 to the Loan Agreement, which changed the aggregate principal amount that may be borrowed under the facility's line of credit up to $ 10.0 million and extended the expiration date of the revolving credit note to March 31, 2025. The Credit Facility bears interest at a rate of the sum of The Secured Overnight Financing Rate (SOFR) plus 125 basis points ( 1.25 %) or the highest of the Prime Rate, the sum of the Overnight Bank Funding Rate plus 50 basis points ( 0.50 %) and the sum of Daily Simple SOFR plus 100 basis points ( 1.00 %). </context> | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
On August 11, 2016 in connection with the Company's IPO, the Board approved the 2016 Incentive Award Plan (the “2016 Plan”). The 2016 Plan provides for long-term equity incentive compensation for key employees, officers and non-employee directors. A variety of discretionary awards (collectively, the “Awards”) for employees and non-employee directors are authorized under the 2016 Plan, including vested shares, stock options, stock appreciation rights (SARs), restricted stock awards (RSAs), restricted stock units (RSUs), or other cash based or stock dividend equivalent awards, which are all equity-classified instruments under the 2016 Plan. The number of shares registered and available for grant under the 2016 Plan is 6,000,000 . The vesting of such awards may be conditioned upon either a specified period of time or the attainment of specific performance goals as determined by the administrator of the 2016 Plan. The option price and term are also subject to determination by the administrator with respect to each grant. Option prices are generally expected to be set at the market price of the Company’s common stock at the date of grant and option terms are not expected to exceed ten years . | text | 6000000 | sharesItemType | text: <entity> 6000000 </entity> <entity type> sharesItemType </entity type> <context> On August 11, 2016 in connection with the Company's IPO, the Board approved the 2016 Incentive Award Plan (the “2016 Plan”). The 2016 Plan provides for long-term equity incentive compensation for key employees, officers and non-employee directors. A variety of discretionary awards (collectively, the “Awards”) for employees and non-employee directors are authorized under the 2016 Plan, including vested shares, stock options, stock appreciation rights (SARs), restricted stock awards (RSAs), restricted stock units (RSUs), or other cash based or stock dividend equivalent awards, which are all equity-classified instruments under the 2016 Plan. The number of shares registered and available for grant under the 2016 Plan is 6,000,000 . The vesting of such awards may be conditioned upon either a specified period of time or the attainment of specific performance goals as determined by the administrator of the 2016 Plan. The option price and term are also subject to determination by the administrator with respect to each grant. Option prices are generally expected to be set at the market price of the Company’s common stock at the date of grant and option terms are not expected to exceed ten years . </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant |
The Company granted 206,893 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2024, consisting of 131,156 RSU and 24,650 stock option awards having five year vesting schedules, 1,087 RSU having four year vesting schedules and 50,000 stock option awards that vested upon issuance. The Company granted an additional 674 RSU that vest in four approximately equal installments on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025, and 6,542 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2024. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. | text | 206893 | sharesItemType | text: <entity> 206893 </entity> <entity type> sharesItemType </entity type> <context> The Company granted 206,893 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2024, consisting of 131,156 RSU and 24,650 stock option awards having five year vesting schedules, 1,087 RSU having four year vesting schedules and 50,000 stock option awards that vested upon issuance. The Company granted an additional 674 RSU that vest in four approximately equal installments on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025, and 6,542 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2024. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod |
The Company granted 206,893 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2024, consisting of 131,156 RSU and 24,650 stock option awards having five year vesting schedules, 1,087 RSU having four year vesting schedules and 50,000 stock option awards that vested upon issuance. The Company granted an additional 674 RSU that vest in four approximately equal installments on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025, and 6,542 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2024. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. | text | 131156 | sharesItemType | text: <entity> 131156 </entity> <entity type> sharesItemType </entity type> <context> The Company granted 206,893 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2024, consisting of 131,156 RSU and 24,650 stock option awards having five year vesting schedules, 1,087 RSU having four year vesting schedules and 50,000 stock option awards that vested upon issuance. The Company granted an additional 674 RSU that vest in four approximately equal installments on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025, and 6,542 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2024. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod |
The Company granted 206,893 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2024, consisting of 131,156 RSU and 24,650 stock option awards having five year vesting schedules, 1,087 RSU having four year vesting schedules and 50,000 stock option awards that vested upon issuance. The Company granted an additional 674 RSU that vest in four approximately equal installments on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025, and 6,542 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2024. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. | text | 24650 | sharesItemType | text: <entity> 24650 </entity> <entity type> sharesItemType </entity type> <context> The Company granted 206,893 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2024, consisting of 131,156 RSU and 24,650 stock option awards having five year vesting schedules, 1,087 RSU having four year vesting schedules and 50,000 stock option awards that vested upon issuance. The Company granted an additional 674 RSU that vest in four approximately equal installments on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025, and 6,542 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2024. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross |
The Company granted 206,893 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2024, consisting of 131,156 RSU and 24,650 stock option awards having five year vesting schedules, 1,087 RSU having four year vesting schedules and 50,000 stock option awards that vested upon issuance. The Company granted an additional 674 RSU that vest in four approximately equal installments on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025, and 6,542 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2024. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. | text | 1087 | sharesItemType | text: <entity> 1087 </entity> <entity type> sharesItemType </entity type> <context> The Company granted 206,893 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2024, consisting of 131,156 RSU and 24,650 stock option awards having five year vesting schedules, 1,087 RSU having four year vesting schedules and 50,000 stock option awards that vested upon issuance. The Company granted an additional 674 RSU that vest in four approximately equal installments on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025, and 6,542 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2024. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod |
The Company granted 206,893 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2024, consisting of 131,156 RSU and 24,650 stock option awards having five year vesting schedules, 1,087 RSU having four year vesting schedules and 50,000 stock option awards that vested upon issuance. The Company granted an additional 674 RSU that vest in four approximately equal installments on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025, and 6,542 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2024. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. | text | 50000 | sharesItemType | text: <entity> 50000 </entity> <entity type> sharesItemType </entity type> <context> The Company granted 206,893 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2024, consisting of 131,156 RSU and 24,650 stock option awards having five year vesting schedules, 1,087 RSU having four year vesting schedules and 50,000 stock option awards that vested upon issuance. The Company granted an additional 674 RSU that vest in four approximately equal installments on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025, and 6,542 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2024. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross |
The Company granted 206,893 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2024, consisting of 131,156 RSU and 24,650 stock option awards having five year vesting schedules, 1,087 RSU having four year vesting schedules and 50,000 stock option awards that vested upon issuance. The Company granted an additional 674 RSU that vest in four approximately equal installments on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025, and 6,542 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2024. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. | text | 674 | sharesItemType | text: <entity> 674 </entity> <entity type> sharesItemType </entity type> <context> The Company granted 206,893 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2024, consisting of 131,156 RSU and 24,650 stock option awards having five year vesting schedules, 1,087 RSU having four year vesting schedules and 50,000 stock option awards that vested upon issuance. The Company granted an additional 674 RSU that vest in four approximately equal installments on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025, and 6,542 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2024. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod |
The Company granted 206,893 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2024, consisting of 131,156 RSU and 24,650 stock option awards having five year vesting schedules, 1,087 RSU having four year vesting schedules and 50,000 stock option awards that vested upon issuance. The Company granted an additional 674 RSU that vest in four approximately equal installments on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025, and 6,542 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2024. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. | text | 6542 | sharesItemType | text: <entity> 6542 </entity> <entity type> sharesItemType </entity type> <context> The Company granted 206,893 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2024, consisting of 131,156 RSU and 24,650 stock option awards having five year vesting schedules, 1,087 RSU having four year vesting schedules and 50,000 stock option awards that vested upon issuance. The Company granted an additional 674 RSU that vest in four approximately equal installments on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025, and 6,542 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2024. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross |
The Company granted 47,238 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2023, consisting of 45,988 RSU and 1,250 stock option awards having four year vesting schedules. The Company granted an additional 848 RSU that vest in four approximately equal installments on March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024, and 11,187 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2023. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. | text | 47238 | sharesItemType | text: <entity> 47238 </entity> <entity type> sharesItemType </entity type> <context> The Company granted 47,238 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2023, consisting of 45,988 RSU and 1,250 stock option awards having four year vesting schedules. The Company granted an additional 848 RSU that vest in four approximately equal installments on March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024, and 11,187 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2023. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod |
The Company granted 47,238 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2023, consisting of 45,988 RSU and 1,250 stock option awards having four year vesting schedules. The Company granted an additional 848 RSU that vest in four approximately equal installments on March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024, and 11,187 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2023. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. | text | 45988 | sharesItemType | text: <entity> 45988 </entity> <entity type> sharesItemType </entity type> <context> The Company granted 47,238 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2023, consisting of 45,988 RSU and 1,250 stock option awards having four year vesting schedules. The Company granted an additional 848 RSU that vest in four approximately equal installments on March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024, and 11,187 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2023. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod |
The Company granted 47,238 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2023, consisting of 45,988 RSU and 1,250 stock option awards having four year vesting schedules. The Company granted an additional 848 RSU that vest in four approximately equal installments on March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024, and 11,187 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2023. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. | text | 1250 | sharesItemType | text: <entity> 1250 </entity> <entity type> sharesItemType </entity type> <context> The Company granted 47,238 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2023, consisting of 45,988 RSU and 1,250 stock option awards having four year vesting schedules. The Company granted an additional 848 RSU that vest in four approximately equal installments on March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024, and 11,187 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2023. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross |
The Company granted 47,238 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2023, consisting of 45,988 RSU and 1,250 stock option awards having four year vesting schedules. The Company granted an additional 848 RSU that vest in four approximately equal installments on March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024, and 11,187 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2023. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. | text | 848 | sharesItemType | text: <entity> 848 </entity> <entity type> sharesItemType </entity type> <context> The Company granted 47,238 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2023, consisting of 45,988 RSU and 1,250 stock option awards having four year vesting schedules. The Company granted an additional 848 RSU that vest in four approximately equal installments on March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024, and 11,187 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2023. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod |
The Company granted 47,238 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2023, consisting of 45,988 RSU and 1,250 stock option awards having four year vesting schedules. The Company granted an additional 848 RSU that vest in four approximately equal installments on March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024, and 11,187 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2023. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. | text | 11187 | sharesItemType | text: <entity> 11187 </entity> <entity type> sharesItemType </entity type> <context> The Company granted 47,238 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2023, consisting of 45,988 RSU and 1,250 stock option awards having four year vesting schedules. The Company granted an additional 848 RSU that vest in four approximately equal installments on March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024, and 11,187 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2023. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross |
The Company granted 405,550 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2022, consisting of 164,478 RSU and 113,838 stock option awards having four year vesting schedules and 127,234 stock option awards having two year vesting schedules. The Company granted an additional 1,117 RSU that vest in four approximately equal installments on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023, and 11,418 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2022. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. | text | 405550 | sharesItemType | text: <entity> 405550 </entity> <entity type> sharesItemType </entity type> <context> The Company granted 405,550 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2022, consisting of 164,478 RSU and 113,838 stock option awards having four year vesting schedules and 127,234 stock option awards having two year vesting schedules. The Company granted an additional 1,117 RSU that vest in four approximately equal installments on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023, and 11,418 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2022. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod |
The Company granted 405,550 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2022, consisting of 164,478 RSU and 113,838 stock option awards having four year vesting schedules and 127,234 stock option awards having two year vesting schedules. The Company granted an additional 1,117 RSU that vest in four approximately equal installments on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023, and 11,418 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2022. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. | text | 164478 | sharesItemType | text: <entity> 164478 </entity> <entity type> sharesItemType </entity type> <context> The Company granted 405,550 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2022, consisting of 164,478 RSU and 113,838 stock option awards having four year vesting schedules and 127,234 stock option awards having two year vesting schedules. The Company granted an additional 1,117 RSU that vest in four approximately equal installments on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023, and 11,418 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2022. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod |
The Company granted 405,550 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2022, consisting of 164,478 RSU and 113,838 stock option awards having four year vesting schedules and 127,234 stock option awards having two year vesting schedules. The Company granted an additional 1,117 RSU that vest in four approximately equal installments on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023, and 11,418 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2022. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. | text | 113838 | sharesItemType | text: <entity> 113838 </entity> <entity type> sharesItemType </entity type> <context> The Company granted 405,550 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2022, consisting of 164,478 RSU and 113,838 stock option awards having four year vesting schedules and 127,234 stock option awards having two year vesting schedules. The Company granted an additional 1,117 RSU that vest in four approximately equal installments on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023, and 11,418 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2022. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross |
The Company granted 405,550 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2022, consisting of 164,478 RSU and 113,838 stock option awards having four year vesting schedules and 127,234 stock option awards having two year vesting schedules. The Company granted an additional 1,117 RSU that vest in four approximately equal installments on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023, and 11,418 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2022. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. | text | 127234 | sharesItemType | text: <entity> 127234 </entity> <entity type> sharesItemType </entity type> <context> The Company granted 405,550 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2022, consisting of 164,478 RSU and 113,838 stock option awards having four year vesting schedules and 127,234 stock option awards having two year vesting schedules. The Company granted an additional 1,117 RSU that vest in four approximately equal installments on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023, and 11,418 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2022. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross |
The Company granted 405,550 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2022, consisting of 164,478 RSU and 113,838 stock option awards having four year vesting schedules and 127,234 stock option awards having two year vesting schedules. The Company granted an additional 1,117 RSU that vest in four approximately equal installments on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023, and 11,418 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2022. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. | text | 1117 | sharesItemType | text: <entity> 1117 </entity> <entity type> sharesItemType </entity type> <context> The Company granted 405,550 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2022, consisting of 164,478 RSU and 113,838 stock option awards having four year vesting schedules and 127,234 stock option awards having two year vesting schedules. The Company granted an additional 1,117 RSU that vest in four approximately equal installments on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023, and 11,418 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2022. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod |
The Company granted 405,550 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2022, consisting of 164,478 RSU and 113,838 stock option awards having four year vesting schedules and 127,234 stock option awards having two year vesting schedules. The Company granted an additional 1,117 RSU that vest in four approximately equal installments on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023, and 11,418 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2022. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. | text | 11418 | sharesItemType | text: <entity> 11418 </entity> <entity type> sharesItemType </entity type> <context> The Company granted 405,550 awards to employees under the 2016 Incentive Award Plan during the year ended December 31, 2022, consisting of 164,478 RSU and 113,838 stock option awards having four year vesting schedules and 127,234 stock option awards having two year vesting schedules. The Company granted an additional 1,117 RSU that vest in four approximately equal installments on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023, and 11,418 stock option awards to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2022. These stock option awards will vest on the earlier of (a) the day immediately preceding the date of the first annual meeting following the date of grant and (b) the first anniversary of the date of grant, subject to the non-employee director continuing in service through the applicable vesting date. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross |
The Company satisfies stock option exercises and vested stock awards with treasury shares or newly issued shares. Shares available for future stock compensation grants under the 2016 Plan totaled 2.1 million and 2.3 million at December 31, 2024 and 2023, respectively. | text | 2.1 | sharesItemType | text: <entity> 2.1 </entity> <entity type> sharesItemType </entity type> <context> The Company satisfies stock option exercises and vested stock awards with treasury shares or newly issued shares. Shares available for future stock compensation grants under the 2016 Plan totaled 2.1 million and 2.3 million at December 31, 2024 and 2023, respectively. </context> | us-gaap:CommonStockCapitalSharesReservedForFutureIssuance |
The Company satisfies stock option exercises and vested stock awards with treasury shares or newly issued shares. Shares available for future stock compensation grants under the 2016 Plan totaled 2.1 million and 2.3 million at December 31, 2024 and 2023, respectively. | text | 2.3 | sharesItemType | text: <entity> 2.3 </entity> <entity type> sharesItemType </entity type> <context> The Company satisfies stock option exercises and vested stock awards with treasury shares or newly issued shares. Shares available for future stock compensation grants under the 2016 Plan totaled 2.1 million and 2.3 million at December 31, 2024 and 2023, respectively. </context> | us-gaap:CommonStockCapitalSharesReservedForFutureIssuance |
The actual tax benefits recognized related to stock-based compensation totaled $ 27.8 million, $ 18.9 million and $ 23.2 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 27.8 | monetaryItemType | text: <entity> 27.8 </entity> <entity type> monetaryItemType </entity type> <context> The actual tax benefits recognized related to stock-based compensation totaled $ 27.8 million, $ 18.9 million and $ 23.2 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense |
The actual tax benefits recognized related to stock-based compensation totaled $ 27.8 million, $ 18.9 million and $ 23.2 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 18.9 | monetaryItemType | text: <entity> 18.9 </entity> <entity type> monetaryItemType </entity type> <context> The actual tax benefits recognized related to stock-based compensation totaled $ 27.8 million, $ 18.9 million and $ 23.2 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense |
The actual tax benefits recognized related to stock-based compensation totaled $ 27.8 million, $ 18.9 million and $ 23.2 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 23.2 | monetaryItemType | text: <entity> 23.2 </entity> <entity type> monetaryItemType </entity type> <context> The actual tax benefits recognized related to stock-based compensation totaled $ 27.8 million, $ 18.9 million and $ 23.2 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense |
The Company provides a 401(k) plan that covers substantially all U.S. employees. Participants can elect to contribute up to 50 % of their eligible earnings on a pre-tax basis, subject to Internal Revenue Service annual limitations. | text | 50 | percentItemType | text: <entity> 50 </entity> <entity type> percentItemType </entity type> <context> The Company provides a 401(k) plan that covers substantially all U.S. employees. Participants can elect to contribute up to 50 % of their eligible earnings on a pre-tax basis, subject to Internal Revenue Service annual limitations. </context> | us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent |
The U.S.-based plan offers a year-end employer matching contribution, requiring the participant to be an employee at year-end to qualify for the match. Participants with one year or more of service are eligible for the matching contribution. Participants fully vest in the employer contributions after three years of service. The employer contribution represents a percentage of a participant’s eligible compensation. The Company’s 401(k) Plan costs were $ 8.9 million, $ 7.4 million and $ 5.4 million during the years ended December 31, 2024, 2023 and 2022, respectively, and were allocated between Total direct costs, and Selling, general and administrative in the consolidated statements of operations. | text | 8.9 | monetaryItemType | text: <entity> 8.9 </entity> <entity type> monetaryItemType </entity type> <context> The U.S.-based plan offers a year-end employer matching contribution, requiring the participant to be an employee at year-end to qualify for the match. Participants with one year or more of service are eligible for the matching contribution. Participants fully vest in the employer contributions after three years of service. The employer contribution represents a percentage of a participant’s eligible compensation. The Company’s 401(k) Plan costs were $ 8.9 million, $ 7.4 million and $ 5.4 million during the years ended December 31, 2024, 2023 and 2022, respectively, and were allocated between Total direct costs, and Selling, general and administrative in the consolidated statements of operations. </context> | us-gaap:DefinedContributionPlanCostRecognized |
The U.S.-based plan offers a year-end employer matching contribution, requiring the participant to be an employee at year-end to qualify for the match. Participants with one year or more of service are eligible for the matching contribution. Participants fully vest in the employer contributions after three years of service. The employer contribution represents a percentage of a participant’s eligible compensation. The Company’s 401(k) Plan costs were $ 8.9 million, $ 7.4 million and $ 5.4 million during the years ended December 31, 2024, 2023 and 2022, respectively, and were allocated between Total direct costs, and Selling, general and administrative in the consolidated statements of operations. | text | 7.4 | monetaryItemType | text: <entity> 7.4 </entity> <entity type> monetaryItemType </entity type> <context> The U.S.-based plan offers a year-end employer matching contribution, requiring the participant to be an employee at year-end to qualify for the match. Participants with one year or more of service are eligible for the matching contribution. Participants fully vest in the employer contributions after three years of service. The employer contribution represents a percentage of a participant’s eligible compensation. The Company’s 401(k) Plan costs were $ 8.9 million, $ 7.4 million and $ 5.4 million during the years ended December 31, 2024, 2023 and 2022, respectively, and were allocated between Total direct costs, and Selling, general and administrative in the consolidated statements of operations. </context> | us-gaap:DefinedContributionPlanCostRecognized |
The U.S.-based plan offers a year-end employer matching contribution, requiring the participant to be an employee at year-end to qualify for the match. Participants with one year or more of service are eligible for the matching contribution. Participants fully vest in the employer contributions after three years of service. The employer contribution represents a percentage of a participant’s eligible compensation. The Company’s 401(k) Plan costs were $ 8.9 million, $ 7.4 million and $ 5.4 million during the years ended December 31, 2024, 2023 and 2022, respectively, and were allocated between Total direct costs, and Selling, general and administrative in the consolidated statements of operations. | text | 5.4 | monetaryItemType | text: <entity> 5.4 </entity> <entity type> monetaryItemType </entity type> <context> The U.S.-based plan offers a year-end employer matching contribution, requiring the participant to be an employee at year-end to qualify for the match. Participants with one year or more of service are eligible for the matching contribution. Participants fully vest in the employer contributions after three years of service. The employer contribution represents a percentage of a participant’s eligible compensation. The Company’s 401(k) Plan costs were $ 8.9 million, $ 7.4 million and $ 5.4 million during the years ended December 31, 2024, 2023 and 2022, respectively, and were allocated between Total direct costs, and Selling, general and administrative in the consolidated statements of operations. </context> | us-gaap:DefinedContributionPlanCostRecognized |
The Company has various defined contribution arrangements for eligible employees of non-U.S. entities. These defined contribution arrangements provide employees with retirement savings and life insurance benefits. The Company incurred expenses related to these arrangements of $ 4.0 million, $ 3.3 million and $ 2.5 million in the years ended December 31, 2024, 2023 and 2022, respectively, and were allocated between Total direct costs, and Selling, general and administrative in the consolidated statements of operations. | text | 4.0 | monetaryItemType | text: <entity> 4.0 </entity> <entity type> monetaryItemType </entity type> <context> The Company has various defined contribution arrangements for eligible employees of non-U.S. entities. These defined contribution arrangements provide employees with retirement savings and life insurance benefits. The Company incurred expenses related to these arrangements of $ 4.0 million, $ 3.3 million and $ 2.5 million in the years ended December 31, 2024, 2023 and 2022, respectively, and were allocated between Total direct costs, and Selling, general and administrative in the consolidated statements of operations. </context> | us-gaap:DefinedContributionPlanCostRecognized |
The Company has various defined contribution arrangements for eligible employees of non-U.S. entities. These defined contribution arrangements provide employees with retirement savings and life insurance benefits. The Company incurred expenses related to these arrangements of $ 4.0 million, $ 3.3 million and $ 2.5 million in the years ended December 31, 2024, 2023 and 2022, respectively, and were allocated between Total direct costs, and Selling, general and administrative in the consolidated statements of operations. | text | 3.3 | monetaryItemType | text: <entity> 3.3 </entity> <entity type> monetaryItemType </entity type> <context> The Company has various defined contribution arrangements for eligible employees of non-U.S. entities. These defined contribution arrangements provide employees with retirement savings and life insurance benefits. The Company incurred expenses related to these arrangements of $ 4.0 million, $ 3.3 million and $ 2.5 million in the years ended December 31, 2024, 2023 and 2022, respectively, and were allocated between Total direct costs, and Selling, general and administrative in the consolidated statements of operations. </context> | us-gaap:DefinedContributionPlanCostRecognized |
The Company has various defined contribution arrangements for eligible employees of non-U.S. entities. These defined contribution arrangements provide employees with retirement savings and life insurance benefits. The Company incurred expenses related to these arrangements of $ 4.0 million, $ 3.3 million and $ 2.5 million in the years ended December 31, 2024, 2023 and 2022, respectively, and were allocated between Total direct costs, and Selling, general and administrative in the consolidated statements of operations. | text | 2.5 | monetaryItemType | text: <entity> 2.5 </entity> <entity type> monetaryItemType </entity type> <context> The Company has various defined contribution arrangements for eligible employees of non-U.S. entities. These defined contribution arrangements provide employees with retirement savings and life insurance benefits. The Company incurred expenses related to these arrangements of $ 4.0 million, $ 3.3 million and $ 2.5 million in the years ended December 31, 2024, 2023 and 2022, respectively, and were allocated between Total direct costs, and Selling, general and administrative in the consolidated statements of operations. </context> | us-gaap:DefinedContributionPlanCostRecognized |
As of December 31, 2024, the Company’s accounting position is that unremitted foreign earnings are indefinitely reinvested. Therefore, the Company has not recorded deferred foreign withholding taxes on the unremitted foreign earnings and it is not practicable to determine the amount of the additional taxes that would result if these earnings were repatriated. The undistributed earnings of foreign subsidiaries was approximately $ 73.2 million for the year ended December 31, 2024. | text | 73.2 | monetaryItemType | text: <entity> 73.2 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company’s accounting position is that unremitted foreign earnings are indefinitely reinvested. Therefore, the Company has not recorded deferred foreign withholding taxes on the unremitted foreign earnings and it is not practicable to determine the amount of the additional taxes that would result if these earnings were repatriated. The undistributed earnings of foreign subsidiaries was approximately $ 73.2 million for the year ended December 31, 2024. </context> | us-gaap:UndistributedEarningsOfForeignSubsidiaries |
The Company has foreign operating loss carryforwards for which a deferred tax asset of $ 0.1 million has been established as of December 31, 2024. The Company does not have a valuation allowance against this deferred tax asset as of December 31, 2024 based upon its assessment that it is more likely than not that this amount will be realized. The ultimate realization of this tax benefit is dependent upon the generation of sufficient operating income in the respective tax jurisdictions. The foreign net operating loss carryforwards will expire in 2028 if not utilized. | text | 0.1 | monetaryItemType | text: <entity> 0.1 </entity> <entity type> monetaryItemType </entity type> <context> The Company has foreign operating loss carryforwards for which a deferred tax asset of $ 0.1 million has been established as of December 31, 2024. The Company does not have a valuation allowance against this deferred tax asset as of December 31, 2024 based upon its assessment that it is more likely than not that this amount will be realized. The ultimate realization of this tax benefit is dependent upon the generation of sufficient operating income in the respective tax jurisdictions. The foreign net operating loss carryforwards will expire in 2028 if not utilized. </context> | us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign |
ended December 31, 2024, 2023 and 2022. As of December 31, 2024 and 2023, respectively, the Company has a liability for interest and penalties of $ 6.7 million and $ 5.2 million that is associated with related tax liabilities of $ 20.3 million and $ 16.2 million for uncertain tax positions. | text | 6.7 | monetaryItemType | text: <entity> 6.7 </entity> <entity type> monetaryItemType </entity type> <context> ended December 31, 2024, 2023 and 2022. As of December 31, 2024 and 2023, respectively, the Company has a liability for interest and penalties of $ 6.7 million and $ 5.2 million that is associated with related tax liabilities of $ 20.3 million and $ 16.2 million for uncertain tax positions. </context> | us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued |
ended December 31, 2024, 2023 and 2022. As of December 31, 2024 and 2023, respectively, the Company has a liability for interest and penalties of $ 6.7 million and $ 5.2 million that is associated with related tax liabilities of $ 20.3 million and $ 16.2 million for uncertain tax positions. | text | 5.2 | monetaryItemType | text: <entity> 5.2 </entity> <entity type> monetaryItemType </entity type> <context> ended December 31, 2024, 2023 and 2022. As of December 31, 2024 and 2023, respectively, the Company has a liability for interest and penalties of $ 6.7 million and $ 5.2 million that is associated with related tax liabilities of $ 20.3 million and $ 16.2 million for uncertain tax positions. </context> | us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued |
ended December 31, 2024, 2023 and 2022. As of December 31, 2024 and 2023, respectively, the Company has a liability for interest and penalties of $ 6.7 million and $ 5.2 million that is associated with related tax liabilities of $ 20.3 million and $ 16.2 million for uncertain tax positions. | text | 20.3 | monetaryItemType | text: <entity> 20.3 </entity> <entity type> monetaryItemType </entity type> <context> ended December 31, 2024, 2023 and 2022. As of December 31, 2024 and 2023, respectively, the Company has a liability for interest and penalties of $ 6.7 million and $ 5.2 million that is associated with related tax liabilities of $ 20.3 million and $ 16.2 million for uncertain tax positions. </context> | us-gaap:LiabilityForUncertainTaxPositionsNoncurrent |
ended December 31, 2024, 2023 and 2022. As of December 31, 2024 and 2023, respectively, the Company has a liability for interest and penalties of $ 6.7 million and $ 5.2 million that is associated with related tax liabilities of $ 20.3 million and $ 16.2 million for uncertain tax positions. | text | 16.2 | monetaryItemType | text: <entity> 16.2 </entity> <entity type> monetaryItemType </entity type> <context> ended December 31, 2024, 2023 and 2022. As of December 31, 2024 and 2023, respectively, the Company has a liability for interest and penalties of $ 6.7 million and $ 5.2 million that is associated with related tax liabilities of $ 20.3 million and $ 16.2 million for uncertain tax positions. </context> | us-gaap:LiabilityForUncertainTaxPositionsNoncurrent |
The Company has several minimum purchase commitments for project related supplies totaling $ 15.6 million as of December 31, 2024. In return for the commitment, Medpace receives preferential pricing. The commitments expire at various times through 2029. | text | 15.6 | monetaryItemType | text: <entity> 15.6 </entity> <entity type> monetaryItemType </entity type> <context> The Company has several minimum purchase commitments for project related supplies totaling $ 15.6 million as of December 31, 2024. In return for the commitment, Medpace receives preferential pricing. The commitments expire at various times through 2029. </context> | us-gaap:LongTermPurchaseCommitmentAmount |
Certain executives and employees of the Company, including the chief executive officer, are members of LIB’s board of managers and/or have equity investments in LIB. The Company entered into a MSA dated November 24, 2015 with LIB, a company that engages in research, development, marketing and commercialization of pharmaceutical drugs. Subsequently, the Company and LIB have entered into several task orders for the Company to perform clinical trial related services. The Company recognized total revenue from LIB of $ 21.7 million, $ 43.7 million and $ 40.5 million during the years ended December 31, 2024, 2023 and 2022, respectively, in the Company’s consolidated statement of operations. As of December 31, 2024 and 2023, the Company had, from LIB, Advanced billings of $ 9.5 million and $ 7.6 million in the consolidated balance sheets, respectively. In addition, the Company had Accounts receivable and unbilled, net from LIB of $ 2.8 million and $ 0.5 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. | text | 21.7 | monetaryItemType | text: <entity> 21.7 </entity> <entity type> monetaryItemType </entity type> <context> Certain executives and employees of the Company, including the chief executive officer, are members of LIB’s board of managers and/or have equity investments in LIB. The Company entered into a MSA dated November 24, 2015 with LIB, a company that engages in research, development, marketing and commercialization of pharmaceutical drugs. Subsequently, the Company and LIB have entered into several task orders for the Company to perform clinical trial related services. The Company recognized total revenue from LIB of $ 21.7 million, $ 43.7 million and $ 40.5 million during the years ended December 31, 2024, 2023 and 2022, respectively, in the Company’s consolidated statement of operations. As of December 31, 2024 and 2023, the Company had, from LIB, Advanced billings of $ 9.5 million and $ 7.6 million in the consolidated balance sheets, respectively. In addition, the Company had Accounts receivable and unbilled, net from LIB of $ 2.8 million and $ 0.5 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. </context> | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
Certain executives and employees of the Company, including the chief executive officer, are members of LIB’s board of managers and/or have equity investments in LIB. The Company entered into a MSA dated November 24, 2015 with LIB, a company that engages in research, development, marketing and commercialization of pharmaceutical drugs. Subsequently, the Company and LIB have entered into several task orders for the Company to perform clinical trial related services. The Company recognized total revenue from LIB of $ 21.7 million, $ 43.7 million and $ 40.5 million during the years ended December 31, 2024, 2023 and 2022, respectively, in the Company’s consolidated statement of operations. As of December 31, 2024 and 2023, the Company had, from LIB, Advanced billings of $ 9.5 million and $ 7.6 million in the consolidated balance sheets, respectively. In addition, the Company had Accounts receivable and unbilled, net from LIB of $ 2.8 million and $ 0.5 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. | text | 43.7 | monetaryItemType | text: <entity> 43.7 </entity> <entity type> monetaryItemType </entity type> <context> Certain executives and employees of the Company, including the chief executive officer, are members of LIB’s board of managers and/or have equity investments in LIB. The Company entered into a MSA dated November 24, 2015 with LIB, a company that engages in research, development, marketing and commercialization of pharmaceutical drugs. Subsequently, the Company and LIB have entered into several task orders for the Company to perform clinical trial related services. The Company recognized total revenue from LIB of $ 21.7 million, $ 43.7 million and $ 40.5 million during the years ended December 31, 2024, 2023 and 2022, respectively, in the Company’s consolidated statement of operations. As of December 31, 2024 and 2023, the Company had, from LIB, Advanced billings of $ 9.5 million and $ 7.6 million in the consolidated balance sheets, respectively. In addition, the Company had Accounts receivable and unbilled, net from LIB of $ 2.8 million and $ 0.5 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. </context> | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
Certain executives and employees of the Company, including the chief executive officer, are members of LIB’s board of managers and/or have equity investments in LIB. The Company entered into a MSA dated November 24, 2015 with LIB, a company that engages in research, development, marketing and commercialization of pharmaceutical drugs. Subsequently, the Company and LIB have entered into several task orders for the Company to perform clinical trial related services. The Company recognized total revenue from LIB of $ 21.7 million, $ 43.7 million and $ 40.5 million during the years ended December 31, 2024, 2023 and 2022, respectively, in the Company’s consolidated statement of operations. As of December 31, 2024 and 2023, the Company had, from LIB, Advanced billings of $ 9.5 million and $ 7.6 million in the consolidated balance sheets, respectively. In addition, the Company had Accounts receivable and unbilled, net from LIB of $ 2.8 million and $ 0.5 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. | text | 40.5 | monetaryItemType | text: <entity> 40.5 </entity> <entity type> monetaryItemType </entity type> <context> Certain executives and employees of the Company, including the chief executive officer, are members of LIB’s board of managers and/or have equity investments in LIB. The Company entered into a MSA dated November 24, 2015 with LIB, a company that engages in research, development, marketing and commercialization of pharmaceutical drugs. Subsequently, the Company and LIB have entered into several task orders for the Company to perform clinical trial related services. The Company recognized total revenue from LIB of $ 21.7 million, $ 43.7 million and $ 40.5 million during the years ended December 31, 2024, 2023 and 2022, respectively, in the Company’s consolidated statement of operations. As of December 31, 2024 and 2023, the Company had, from LIB, Advanced billings of $ 9.5 million and $ 7.6 million in the consolidated balance sheets, respectively. In addition, the Company had Accounts receivable and unbilled, net from LIB of $ 2.8 million and $ 0.5 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. </context> | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
Certain executives and employees of the Company, including the chief executive officer, are members of LIB’s board of managers and/or have equity investments in LIB. The Company entered into a MSA dated November 24, 2015 with LIB, a company that engages in research, development, marketing and commercialization of pharmaceutical drugs. Subsequently, the Company and LIB have entered into several task orders for the Company to perform clinical trial related services. The Company recognized total revenue from LIB of $ 21.7 million, $ 43.7 million and $ 40.5 million during the years ended December 31, 2024, 2023 and 2022, respectively, in the Company’s consolidated statement of operations. As of December 31, 2024 and 2023, the Company had, from LIB, Advanced billings of $ 9.5 million and $ 7.6 million in the consolidated balance sheets, respectively. In addition, the Company had Accounts receivable and unbilled, net from LIB of $ 2.8 million and $ 0.5 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. | text | 9.5 | monetaryItemType | text: <entity> 9.5 </entity> <entity type> monetaryItemType </entity type> <context> Certain executives and employees of the Company, including the chief executive officer, are members of LIB’s board of managers and/or have equity investments in LIB. The Company entered into a MSA dated November 24, 2015 with LIB, a company that engages in research, development, marketing and commercialization of pharmaceutical drugs. Subsequently, the Company and LIB have entered into several task orders for the Company to perform clinical trial related services. The Company recognized total revenue from LIB of $ 21.7 million, $ 43.7 million and $ 40.5 million during the years ended December 31, 2024, 2023 and 2022, respectively, in the Company’s consolidated statement of operations. As of December 31, 2024 and 2023, the Company had, from LIB, Advanced billings of $ 9.5 million and $ 7.6 million in the consolidated balance sheets, respectively. In addition, the Company had Accounts receivable and unbilled, net from LIB of $ 2.8 million and $ 0.5 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. </context> | us-gaap:ContractWithCustomerLiabilityCurrent |
Certain executives and employees of the Company, including the chief executive officer, are members of LIB’s board of managers and/or have equity investments in LIB. The Company entered into a MSA dated November 24, 2015 with LIB, a company that engages in research, development, marketing and commercialization of pharmaceutical drugs. Subsequently, the Company and LIB have entered into several task orders for the Company to perform clinical trial related services. The Company recognized total revenue from LIB of $ 21.7 million, $ 43.7 million and $ 40.5 million during the years ended December 31, 2024, 2023 and 2022, respectively, in the Company’s consolidated statement of operations. As of December 31, 2024 and 2023, the Company had, from LIB, Advanced billings of $ 9.5 million and $ 7.6 million in the consolidated balance sheets, respectively. In addition, the Company had Accounts receivable and unbilled, net from LIB of $ 2.8 million and $ 0.5 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. | text | 7.6 | monetaryItemType | text: <entity> 7.6 </entity> <entity type> monetaryItemType </entity type> <context> Certain executives and employees of the Company, including the chief executive officer, are members of LIB’s board of managers and/or have equity investments in LIB. The Company entered into a MSA dated November 24, 2015 with LIB, a company that engages in research, development, marketing and commercialization of pharmaceutical drugs. Subsequently, the Company and LIB have entered into several task orders for the Company to perform clinical trial related services. The Company recognized total revenue from LIB of $ 21.7 million, $ 43.7 million and $ 40.5 million during the years ended December 31, 2024, 2023 and 2022, respectively, in the Company’s consolidated statement of operations. As of December 31, 2024 and 2023, the Company had, from LIB, Advanced billings of $ 9.5 million and $ 7.6 million in the consolidated balance sheets, respectively. In addition, the Company had Accounts receivable and unbilled, net from LIB of $ 2.8 million and $ 0.5 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. </context> | us-gaap:ContractWithCustomerLiabilityCurrent |
Certain executives and employees of the Company, including the chief executive officer, are members of LIB’s board of managers and/or have equity investments in LIB. The Company entered into a MSA dated November 24, 2015 with LIB, a company that engages in research, development, marketing and commercialization of pharmaceutical drugs. Subsequently, the Company and LIB have entered into several task orders for the Company to perform clinical trial related services. The Company recognized total revenue from LIB of $ 21.7 million, $ 43.7 million and $ 40.5 million during the years ended December 31, 2024, 2023 and 2022, respectively, in the Company’s consolidated statement of operations. As of December 31, 2024 and 2023, the Company had, from LIB, Advanced billings of $ 9.5 million and $ 7.6 million in the consolidated balance sheets, respectively. In addition, the Company had Accounts receivable and unbilled, net from LIB of $ 2.8 million and $ 0.5 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. | text | 2.8 | monetaryItemType | text: <entity> 2.8 </entity> <entity type> monetaryItemType </entity type> <context> Certain executives and employees of the Company, including the chief executive officer, are members of LIB’s board of managers and/or have equity investments in LIB. The Company entered into a MSA dated November 24, 2015 with LIB, a company that engages in research, development, marketing and commercialization of pharmaceutical drugs. Subsequently, the Company and LIB have entered into several task orders for the Company to perform clinical trial related services. The Company recognized total revenue from LIB of $ 21.7 million, $ 43.7 million and $ 40.5 million during the years ended December 31, 2024, 2023 and 2022, respectively, in the Company’s consolidated statement of operations. As of December 31, 2024 and 2023, the Company had, from LIB, Advanced billings of $ 9.5 million and $ 7.6 million in the consolidated balance sheets, respectively. In addition, the Company had Accounts receivable and unbilled, net from LIB of $ 2.8 million and $ 0.5 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. </context> | us-gaap:ReceivablesNetCurrent |
Certain executives and employees of the Company, including the chief executive officer, are members of LIB’s board of managers and/or have equity investments in LIB. The Company entered into a MSA dated November 24, 2015 with LIB, a company that engages in research, development, marketing and commercialization of pharmaceutical drugs. Subsequently, the Company and LIB have entered into several task orders for the Company to perform clinical trial related services. The Company recognized total revenue from LIB of $ 21.7 million, $ 43.7 million and $ 40.5 million during the years ended December 31, 2024, 2023 and 2022, respectively, in the Company’s consolidated statement of operations. As of December 31, 2024 and 2023, the Company had, from LIB, Advanced billings of $ 9.5 million and $ 7.6 million in the consolidated balance sheets, respectively. In addition, the Company had Accounts receivable and unbilled, net from LIB of $ 2.8 million and $ 0.5 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. | text | 0.5 | monetaryItemType | text: <entity> 0.5 </entity> <entity type> monetaryItemType </entity type> <context> Certain executives and employees of the Company, including the chief executive officer, are members of LIB’s board of managers and/or have equity investments in LIB. The Company entered into a MSA dated November 24, 2015 with LIB, a company that engages in research, development, marketing and commercialization of pharmaceutical drugs. Subsequently, the Company and LIB have entered into several task orders for the Company to perform clinical trial related services. The Company recognized total revenue from LIB of $ 21.7 million, $ 43.7 million and $ 40.5 million during the years ended December 31, 2024, 2023 and 2022, respectively, in the Company’s consolidated statement of operations. As of December 31, 2024 and 2023, the Company had, from LIB, Advanced billings of $ 9.5 million and $ 7.6 million in the consolidated balance sheets, respectively. In addition, the Company had Accounts receivable and unbilled, net from LIB of $ 2.8 million and $ 0.5 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. </context> | us-gaap:ReceivablesNetCurrent |
Certain executives and employees of the Company, including the chief executive officer, are members of CinRx’s board of managers and/or have equity investments in CinRx, a biotech company. The Company and CinRx have entered into several task orders for the Company to perform clinical trial related services. During the years ended December 31, 2024, 2023 and 2022, the Company recognized total revenue from CinRx of $ 28.3 million, $ 15.8 million and $ 15.0 million in the Company’s consolidated statements of operations, respectively. As of December 31, 2024 and 2023, the Company had Advanced billings from CinRx of $ 5.2 million and $ 2.5 million in the consolidated balance sheets, respectively. As of December 31, 2024 and 2023 the Company had Accounts receivable and unbilled, net from CinRx of $ 1.4 million and $ 1.9 million in the consolidated balance sheets, respectively. The Company had Prepaid expenses and other current assets with CinRX of $ 0.1 million and $ 0.2 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. Certain affiliates of CinRx included in previous reported periods are no longer disclosed due to changes in the affiliate relationship. | text | 28.3 | monetaryItemType | text: <entity> 28.3 </entity> <entity type> monetaryItemType </entity type> <context> Certain executives and employees of the Company, including the chief executive officer, are members of CinRx’s board of managers and/or have equity investments in CinRx, a biotech company. The Company and CinRx have entered into several task orders for the Company to perform clinical trial related services. During the years ended December 31, 2024, 2023 and 2022, the Company recognized total revenue from CinRx of $ 28.3 million, $ 15.8 million and $ 15.0 million in the Company’s consolidated statements of operations, respectively. As of December 31, 2024 and 2023, the Company had Advanced billings from CinRx of $ 5.2 million and $ 2.5 million in the consolidated balance sheets, respectively. As of December 31, 2024 and 2023 the Company had Accounts receivable and unbilled, net from CinRx of $ 1.4 million and $ 1.9 million in the consolidated balance sheets, respectively. The Company had Prepaid expenses and other current assets with CinRX of $ 0.1 million and $ 0.2 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. Certain affiliates of CinRx included in previous reported periods are no longer disclosed due to changes in the affiliate relationship. </context> | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
Certain executives and employees of the Company, including the chief executive officer, are members of CinRx’s board of managers and/or have equity investments in CinRx, a biotech company. The Company and CinRx have entered into several task orders for the Company to perform clinical trial related services. During the years ended December 31, 2024, 2023 and 2022, the Company recognized total revenue from CinRx of $ 28.3 million, $ 15.8 million and $ 15.0 million in the Company’s consolidated statements of operations, respectively. As of December 31, 2024 and 2023, the Company had Advanced billings from CinRx of $ 5.2 million and $ 2.5 million in the consolidated balance sheets, respectively. As of December 31, 2024 and 2023 the Company had Accounts receivable and unbilled, net from CinRx of $ 1.4 million and $ 1.9 million in the consolidated balance sheets, respectively. The Company had Prepaid expenses and other current assets with CinRX of $ 0.1 million and $ 0.2 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. Certain affiliates of CinRx included in previous reported periods are no longer disclosed due to changes in the affiliate relationship. | text | 15.8 | monetaryItemType | text: <entity> 15.8 </entity> <entity type> monetaryItemType </entity type> <context> Certain executives and employees of the Company, including the chief executive officer, are members of CinRx’s board of managers and/or have equity investments in CinRx, a biotech company. The Company and CinRx have entered into several task orders for the Company to perform clinical trial related services. During the years ended December 31, 2024, 2023 and 2022, the Company recognized total revenue from CinRx of $ 28.3 million, $ 15.8 million and $ 15.0 million in the Company’s consolidated statements of operations, respectively. As of December 31, 2024 and 2023, the Company had Advanced billings from CinRx of $ 5.2 million and $ 2.5 million in the consolidated balance sheets, respectively. As of December 31, 2024 and 2023 the Company had Accounts receivable and unbilled, net from CinRx of $ 1.4 million and $ 1.9 million in the consolidated balance sheets, respectively. The Company had Prepaid expenses and other current assets with CinRX of $ 0.1 million and $ 0.2 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. Certain affiliates of CinRx included in previous reported periods are no longer disclosed due to changes in the affiliate relationship. </context> | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
Certain executives and employees of the Company, including the chief executive officer, are members of CinRx’s board of managers and/or have equity investments in CinRx, a biotech company. The Company and CinRx have entered into several task orders for the Company to perform clinical trial related services. During the years ended December 31, 2024, 2023 and 2022, the Company recognized total revenue from CinRx of $ 28.3 million, $ 15.8 million and $ 15.0 million in the Company’s consolidated statements of operations, respectively. As of December 31, 2024 and 2023, the Company had Advanced billings from CinRx of $ 5.2 million and $ 2.5 million in the consolidated balance sheets, respectively. As of December 31, 2024 and 2023 the Company had Accounts receivable and unbilled, net from CinRx of $ 1.4 million and $ 1.9 million in the consolidated balance sheets, respectively. The Company had Prepaid expenses and other current assets with CinRX of $ 0.1 million and $ 0.2 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. Certain affiliates of CinRx included in previous reported periods are no longer disclosed due to changes in the affiliate relationship. | text | 15.0 | monetaryItemType | text: <entity> 15.0 </entity> <entity type> monetaryItemType </entity type> <context> Certain executives and employees of the Company, including the chief executive officer, are members of CinRx’s board of managers and/or have equity investments in CinRx, a biotech company. The Company and CinRx have entered into several task orders for the Company to perform clinical trial related services. During the years ended December 31, 2024, 2023 and 2022, the Company recognized total revenue from CinRx of $ 28.3 million, $ 15.8 million and $ 15.0 million in the Company’s consolidated statements of operations, respectively. As of December 31, 2024 and 2023, the Company had Advanced billings from CinRx of $ 5.2 million and $ 2.5 million in the consolidated balance sheets, respectively. As of December 31, 2024 and 2023 the Company had Accounts receivable and unbilled, net from CinRx of $ 1.4 million and $ 1.9 million in the consolidated balance sheets, respectively. The Company had Prepaid expenses and other current assets with CinRX of $ 0.1 million and $ 0.2 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. Certain affiliates of CinRx included in previous reported periods are no longer disclosed due to changes in the affiliate relationship. </context> | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
Certain executives and employees of the Company, including the chief executive officer, are members of CinRx’s board of managers and/or have equity investments in CinRx, a biotech company. The Company and CinRx have entered into several task orders for the Company to perform clinical trial related services. During the years ended December 31, 2024, 2023 and 2022, the Company recognized total revenue from CinRx of $ 28.3 million, $ 15.8 million and $ 15.0 million in the Company’s consolidated statements of operations, respectively. As of December 31, 2024 and 2023, the Company had Advanced billings from CinRx of $ 5.2 million and $ 2.5 million in the consolidated balance sheets, respectively. As of December 31, 2024 and 2023 the Company had Accounts receivable and unbilled, net from CinRx of $ 1.4 million and $ 1.9 million in the consolidated balance sheets, respectively. The Company had Prepaid expenses and other current assets with CinRX of $ 0.1 million and $ 0.2 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. Certain affiliates of CinRx included in previous reported periods are no longer disclosed due to changes in the affiliate relationship. | text | 5.2 | monetaryItemType | text: <entity> 5.2 </entity> <entity type> monetaryItemType </entity type> <context> Certain executives and employees of the Company, including the chief executive officer, are members of CinRx’s board of managers and/or have equity investments in CinRx, a biotech company. The Company and CinRx have entered into several task orders for the Company to perform clinical trial related services. During the years ended December 31, 2024, 2023 and 2022, the Company recognized total revenue from CinRx of $ 28.3 million, $ 15.8 million and $ 15.0 million in the Company’s consolidated statements of operations, respectively. As of December 31, 2024 and 2023, the Company had Advanced billings from CinRx of $ 5.2 million and $ 2.5 million in the consolidated balance sheets, respectively. As of December 31, 2024 and 2023 the Company had Accounts receivable and unbilled, net from CinRx of $ 1.4 million and $ 1.9 million in the consolidated balance sheets, respectively. The Company had Prepaid expenses and other current assets with CinRX of $ 0.1 million and $ 0.2 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. Certain affiliates of CinRx included in previous reported periods are no longer disclosed due to changes in the affiliate relationship. </context> | us-gaap:ContractWithCustomerLiabilityCurrent |
Certain executives and employees of the Company, including the chief executive officer, are members of CinRx’s board of managers and/or have equity investments in CinRx, a biotech company. The Company and CinRx have entered into several task orders for the Company to perform clinical trial related services. During the years ended December 31, 2024, 2023 and 2022, the Company recognized total revenue from CinRx of $ 28.3 million, $ 15.8 million and $ 15.0 million in the Company’s consolidated statements of operations, respectively. As of December 31, 2024 and 2023, the Company had Advanced billings from CinRx of $ 5.2 million and $ 2.5 million in the consolidated balance sheets, respectively. As of December 31, 2024 and 2023 the Company had Accounts receivable and unbilled, net from CinRx of $ 1.4 million and $ 1.9 million in the consolidated balance sheets, respectively. The Company had Prepaid expenses and other current assets with CinRX of $ 0.1 million and $ 0.2 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. Certain affiliates of CinRx included in previous reported periods are no longer disclosed due to changes in the affiliate relationship. | text | 2.5 | monetaryItemType | text: <entity> 2.5 </entity> <entity type> monetaryItemType </entity type> <context> Certain executives and employees of the Company, including the chief executive officer, are members of CinRx’s board of managers and/or have equity investments in CinRx, a biotech company. The Company and CinRx have entered into several task orders for the Company to perform clinical trial related services. During the years ended December 31, 2024, 2023 and 2022, the Company recognized total revenue from CinRx of $ 28.3 million, $ 15.8 million and $ 15.0 million in the Company’s consolidated statements of operations, respectively. As of December 31, 2024 and 2023, the Company had Advanced billings from CinRx of $ 5.2 million and $ 2.5 million in the consolidated balance sheets, respectively. As of December 31, 2024 and 2023 the Company had Accounts receivable and unbilled, net from CinRx of $ 1.4 million and $ 1.9 million in the consolidated balance sheets, respectively. The Company had Prepaid expenses and other current assets with CinRX of $ 0.1 million and $ 0.2 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. Certain affiliates of CinRx included in previous reported periods are no longer disclosed due to changes in the affiliate relationship. </context> | us-gaap:ContractWithCustomerLiabilityCurrent |
Certain executives and employees of the Company, including the chief executive officer, are members of CinRx’s board of managers and/or have equity investments in CinRx, a biotech company. The Company and CinRx have entered into several task orders for the Company to perform clinical trial related services. During the years ended December 31, 2024, 2023 and 2022, the Company recognized total revenue from CinRx of $ 28.3 million, $ 15.8 million and $ 15.0 million in the Company’s consolidated statements of operations, respectively. As of December 31, 2024 and 2023, the Company had Advanced billings from CinRx of $ 5.2 million and $ 2.5 million in the consolidated balance sheets, respectively. As of December 31, 2024 and 2023 the Company had Accounts receivable and unbilled, net from CinRx of $ 1.4 million and $ 1.9 million in the consolidated balance sheets, respectively. The Company had Prepaid expenses and other current assets with CinRX of $ 0.1 million and $ 0.2 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. Certain affiliates of CinRx included in previous reported periods are no longer disclosed due to changes in the affiliate relationship. | text | 1.4 | monetaryItemType | text: <entity> 1.4 </entity> <entity type> monetaryItemType </entity type> <context> Certain executives and employees of the Company, including the chief executive officer, are members of CinRx’s board of managers and/or have equity investments in CinRx, a biotech company. The Company and CinRx have entered into several task orders for the Company to perform clinical trial related services. During the years ended December 31, 2024, 2023 and 2022, the Company recognized total revenue from CinRx of $ 28.3 million, $ 15.8 million and $ 15.0 million in the Company’s consolidated statements of operations, respectively. As of December 31, 2024 and 2023, the Company had Advanced billings from CinRx of $ 5.2 million and $ 2.5 million in the consolidated balance sheets, respectively. As of December 31, 2024 and 2023 the Company had Accounts receivable and unbilled, net from CinRx of $ 1.4 million and $ 1.9 million in the consolidated balance sheets, respectively. The Company had Prepaid expenses and other current assets with CinRX of $ 0.1 million and $ 0.2 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. Certain affiliates of CinRx included in previous reported periods are no longer disclosed due to changes in the affiliate relationship. </context> | us-gaap:ReceivablesNetCurrent |
Certain executives and employees of the Company, including the chief executive officer, are members of CinRx’s board of managers and/or have equity investments in CinRx, a biotech company. The Company and CinRx have entered into several task orders for the Company to perform clinical trial related services. During the years ended December 31, 2024, 2023 and 2022, the Company recognized total revenue from CinRx of $ 28.3 million, $ 15.8 million and $ 15.0 million in the Company’s consolidated statements of operations, respectively. As of December 31, 2024 and 2023, the Company had Advanced billings from CinRx of $ 5.2 million and $ 2.5 million in the consolidated balance sheets, respectively. As of December 31, 2024 and 2023 the Company had Accounts receivable and unbilled, net from CinRx of $ 1.4 million and $ 1.9 million in the consolidated balance sheets, respectively. The Company had Prepaid expenses and other current assets with CinRX of $ 0.1 million and $ 0.2 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. Certain affiliates of CinRx included in previous reported periods are no longer disclosed due to changes in the affiliate relationship. | text | 1.9 | monetaryItemType | text: <entity> 1.9 </entity> <entity type> monetaryItemType </entity type> <context> Certain executives and employees of the Company, including the chief executive officer, are members of CinRx’s board of managers and/or have equity investments in CinRx, a biotech company. The Company and CinRx have entered into several task orders for the Company to perform clinical trial related services. During the years ended December 31, 2024, 2023 and 2022, the Company recognized total revenue from CinRx of $ 28.3 million, $ 15.8 million and $ 15.0 million in the Company’s consolidated statements of operations, respectively. As of December 31, 2024 and 2023, the Company had Advanced billings from CinRx of $ 5.2 million and $ 2.5 million in the consolidated balance sheets, respectively. As of December 31, 2024 and 2023 the Company had Accounts receivable and unbilled, net from CinRx of $ 1.4 million and $ 1.9 million in the consolidated balance sheets, respectively. The Company had Prepaid expenses and other current assets with CinRX of $ 0.1 million and $ 0.2 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. Certain affiliates of CinRx included in previous reported periods are no longer disclosed due to changes in the affiliate relationship. </context> | us-gaap:ReceivablesNetCurrent |
Certain executives and employees of the Company, including the chief executive officer, are members of CinRx’s board of managers and/or have equity investments in CinRx, a biotech company. The Company and CinRx have entered into several task orders for the Company to perform clinical trial related services. During the years ended December 31, 2024, 2023 and 2022, the Company recognized total revenue from CinRx of $ 28.3 million, $ 15.8 million and $ 15.0 million in the Company’s consolidated statements of operations, respectively. As of December 31, 2024 and 2023, the Company had Advanced billings from CinRx of $ 5.2 million and $ 2.5 million in the consolidated balance sheets, respectively. As of December 31, 2024 and 2023 the Company had Accounts receivable and unbilled, net from CinRx of $ 1.4 million and $ 1.9 million in the consolidated balance sheets, respectively. The Company had Prepaid expenses and other current assets with CinRX of $ 0.1 million and $ 0.2 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. Certain affiliates of CinRx included in previous reported periods are no longer disclosed due to changes in the affiliate relationship. | text | 0.1 | monetaryItemType | text: <entity> 0.1 </entity> <entity type> monetaryItemType </entity type> <context> Certain executives and employees of the Company, including the chief executive officer, are members of CinRx’s board of managers and/or have equity investments in CinRx, a biotech company. The Company and CinRx have entered into several task orders for the Company to perform clinical trial related services. During the years ended December 31, 2024, 2023 and 2022, the Company recognized total revenue from CinRx of $ 28.3 million, $ 15.8 million and $ 15.0 million in the Company’s consolidated statements of operations, respectively. As of December 31, 2024 and 2023, the Company had Advanced billings from CinRx of $ 5.2 million and $ 2.5 million in the consolidated balance sheets, respectively. As of December 31, 2024 and 2023 the Company had Accounts receivable and unbilled, net from CinRx of $ 1.4 million and $ 1.9 million in the consolidated balance sheets, respectively. The Company had Prepaid expenses and other current assets with CinRX of $ 0.1 million and $ 0.2 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. Certain affiliates of CinRx included in previous reported periods are no longer disclosed due to changes in the affiliate relationship. </context> | us-gaap:PrepaidExpenseAndOtherAssetsCurrent |
Certain executives and employees of the Company, including the chief executive officer, are members of CinRx’s board of managers and/or have equity investments in CinRx, a biotech company. The Company and CinRx have entered into several task orders for the Company to perform clinical trial related services. During the years ended December 31, 2024, 2023 and 2022, the Company recognized total revenue from CinRx of $ 28.3 million, $ 15.8 million and $ 15.0 million in the Company’s consolidated statements of operations, respectively. As of December 31, 2024 and 2023, the Company had Advanced billings from CinRx of $ 5.2 million and $ 2.5 million in the consolidated balance sheets, respectively. As of December 31, 2024 and 2023 the Company had Accounts receivable and unbilled, net from CinRx of $ 1.4 million and $ 1.9 million in the consolidated balance sheets, respectively. The Company had Prepaid expenses and other current assets with CinRX of $ 0.1 million and $ 0.2 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. Certain affiliates of CinRx included in previous reported periods are no longer disclosed due to changes in the affiliate relationship. | text | 0.2 | monetaryItemType | text: <entity> 0.2 </entity> <entity type> monetaryItemType </entity type> <context> Certain executives and employees of the Company, including the chief executive officer, are members of CinRx’s board of managers and/or have equity investments in CinRx, a biotech company. The Company and CinRx have entered into several task orders for the Company to perform clinical trial related services. During the years ended December 31, 2024, 2023 and 2022, the Company recognized total revenue from CinRx of $ 28.3 million, $ 15.8 million and $ 15.0 million in the Company’s consolidated statements of operations, respectively. As of December 31, 2024 and 2023, the Company had Advanced billings from CinRx of $ 5.2 million and $ 2.5 million in the consolidated balance sheets, respectively. As of December 31, 2024 and 2023 the Company had Accounts receivable and unbilled, net from CinRx of $ 1.4 million and $ 1.9 million in the consolidated balance sheets, respectively. The Company had Prepaid expenses and other current assets with CinRX of $ 0.1 million and $ 0.2 million in the consolidated balance sheets at December 31, 2024 and 2023, respectively. Certain affiliates of CinRx included in previous reported periods are no longer disclosed due to changes in the affiliate relationship. </context> | us-gaap:PrepaidExpenseAndOtherAssetsCurrent |
The Summit Hotel, located on the Medpace campus, is owned by the chief executive officer. Medpace incurs travel lodging and meeting expenses at The Summit. During the years ended December 31, 2024, 2023 and 2022, Medpace incurred expenses of $ 0.3 million, $ 0.4 million and $ 0.3 million at The Summit, respectively. | text | 0.3 | monetaryItemType | text: <entity> 0.3 </entity> <entity type> monetaryItemType </entity type> <context> The Summit Hotel, located on the Medpace campus, is owned by the chief executive officer. Medpace incurs travel lodging and meeting expenses at The Summit. During the years ended December 31, 2024, 2023 and 2022, Medpace incurred expenses of $ 0.3 million, $ 0.4 million and $ 0.3 million at The Summit, respectively. </context> | us-gaap:OperatingCostsAndExpenses |
The Summit Hotel, located on the Medpace campus, is owned by the chief executive officer. Medpace incurs travel lodging and meeting expenses at The Summit. During the years ended December 31, 2024, 2023 and 2022, Medpace incurred expenses of $ 0.3 million, $ 0.4 million and $ 0.3 million at The Summit, respectively. | text | 0.4 | monetaryItemType | text: <entity> 0.4 </entity> <entity type> monetaryItemType </entity type> <context> The Summit Hotel, located on the Medpace campus, is owned by the chief executive officer. Medpace incurs travel lodging and meeting expenses at The Summit. During the years ended December 31, 2024, 2023 and 2022, Medpace incurred expenses of $ 0.3 million, $ 0.4 million and $ 0.3 million at The Summit, respectively. </context> | us-gaap:OperatingCostsAndExpenses |
The Company entered into an operating lease for the occupancy of office space in a building in Cincinnati, Ohio with an entity that is wholly owned by the chief executive officer of the Company. The Company has evaluated its relationship with the related party and concluded that the related party is not a variable interest entity because the Company has no direct ownership interest or relationship other than the leases. The lease was renewed in the first quarter of fiscal year 2023 for a term of ten years through December 2032 with a renewal option for one 10-year term at prevailing market rates. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the properties. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.7 million, $ 2.6 million and 2.3 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 17.6 million and $ 19.3 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.6 million and $ 16.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.5 million and $ 18.1 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. | text | 2.7 | monetaryItemType | text: <entity> 2.7 </entity> <entity type> monetaryItemType </entity type> <context> The Company entered into an operating lease for the occupancy of office space in a building in Cincinnati, Ohio with an entity that is wholly owned by the chief executive officer of the Company. The Company has evaluated its relationship with the related party and concluded that the related party is not a variable interest entity because the Company has no direct ownership interest or relationship other than the leases. The lease was renewed in the first quarter of fiscal year 2023 for a term of ten years through December 2032 with a renewal option for one 10-year term at prevailing market rates. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the properties. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.7 million, $ 2.6 million and 2.3 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 17.6 million and $ 19.3 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.6 million and $ 16.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.5 million and $ 18.1 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. </context> | us-gaap:OperatingLeaseCost |
The Company entered into an operating lease for the occupancy of office space in a building in Cincinnati, Ohio with an entity that is wholly owned by the chief executive officer of the Company. The Company has evaluated its relationship with the related party and concluded that the related party is not a variable interest entity because the Company has no direct ownership interest or relationship other than the leases. The lease was renewed in the first quarter of fiscal year 2023 for a term of ten years through December 2032 with a renewal option for one 10-year term at prevailing market rates. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the properties. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.7 million, $ 2.6 million and 2.3 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 17.6 million and $ 19.3 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.6 million and $ 16.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.5 million and $ 18.1 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. | text | 2.6 | monetaryItemType | text: <entity> 2.6 </entity> <entity type> monetaryItemType </entity type> <context> The Company entered into an operating lease for the occupancy of office space in a building in Cincinnati, Ohio with an entity that is wholly owned by the chief executive officer of the Company. The Company has evaluated its relationship with the related party and concluded that the related party is not a variable interest entity because the Company has no direct ownership interest or relationship other than the leases. The lease was renewed in the first quarter of fiscal year 2023 for a term of ten years through December 2032 with a renewal option for one 10-year term at prevailing market rates. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the properties. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.7 million, $ 2.6 million and 2.3 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 17.6 million and $ 19.3 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.6 million and $ 16.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.5 million and $ 18.1 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. </context> | us-gaap:OperatingLeaseCost |
The Company entered into an operating lease for the occupancy of office space in a building in Cincinnati, Ohio with an entity that is wholly owned by the chief executive officer of the Company. The Company has evaluated its relationship with the related party and concluded that the related party is not a variable interest entity because the Company has no direct ownership interest or relationship other than the leases. The lease was renewed in the first quarter of fiscal year 2023 for a term of ten years through December 2032 with a renewal option for one 10-year term at prevailing market rates. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the properties. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.7 million, $ 2.6 million and 2.3 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 17.6 million and $ 19.3 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.6 million and $ 16.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.5 million and $ 18.1 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. | text | 2.3 | monetaryItemType | text: <entity> 2.3 </entity> <entity type> monetaryItemType </entity type> <context> The Company entered into an operating lease for the occupancy of office space in a building in Cincinnati, Ohio with an entity that is wholly owned by the chief executive officer of the Company. The Company has evaluated its relationship with the related party and concluded that the related party is not a variable interest entity because the Company has no direct ownership interest or relationship other than the leases. The lease was renewed in the first quarter of fiscal year 2023 for a term of ten years through December 2032 with a renewal option for one 10-year term at prevailing market rates. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the properties. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.7 million, $ 2.6 million and 2.3 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 17.6 million and $ 19.3 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.6 million and $ 16.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.5 million and $ 18.1 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. </context> | us-gaap:OperatingLeaseCost |
The Company entered into an operating lease for the occupancy of office space in a building in Cincinnati, Ohio with an entity that is wholly owned by the chief executive officer of the Company. The Company has evaluated its relationship with the related party and concluded that the related party is not a variable interest entity because the Company has no direct ownership interest or relationship other than the leases. The lease was renewed in the first quarter of fiscal year 2023 for a term of ten years through December 2032 with a renewal option for one 10-year term at prevailing market rates. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the properties. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.7 million, $ 2.6 million and 2.3 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 17.6 million and $ 19.3 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.6 million and $ 16.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.5 million and $ 18.1 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. | text | 17.6 | monetaryItemType | text: <entity> 17.6 </entity> <entity type> monetaryItemType </entity type> <context> The Company entered into an operating lease for the occupancy of office space in a building in Cincinnati, Ohio with an entity that is wholly owned by the chief executive officer of the Company. The Company has evaluated its relationship with the related party and concluded that the related party is not a variable interest entity because the Company has no direct ownership interest or relationship other than the leases. The lease was renewed in the first quarter of fiscal year 2023 for a term of ten years through December 2032 with a renewal option for one 10-year term at prevailing market rates. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the properties. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.7 million, $ 2.6 million and 2.3 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 17.6 million and $ 19.3 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.6 million and $ 16.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.5 million and $ 18.1 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. </context> | us-gaap:OperatingLeaseRightOfUseAsset |
The Company entered into an operating lease for the occupancy of office space in a building in Cincinnati, Ohio with an entity that is wholly owned by the chief executive officer of the Company. The Company has evaluated its relationship with the related party and concluded that the related party is not a variable interest entity because the Company has no direct ownership interest or relationship other than the leases. The lease was renewed in the first quarter of fiscal year 2023 for a term of ten years through December 2032 with a renewal option for one 10-year term at prevailing market rates. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the properties. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.7 million, $ 2.6 million and 2.3 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 17.6 million and $ 19.3 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.6 million and $ 16.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.5 million and $ 18.1 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. | text | 19.3 | monetaryItemType | text: <entity> 19.3 </entity> <entity type> monetaryItemType </entity type> <context> The Company entered into an operating lease for the occupancy of office space in a building in Cincinnati, Ohio with an entity that is wholly owned by the chief executive officer of the Company. The Company has evaluated its relationship with the related party and concluded that the related party is not a variable interest entity because the Company has no direct ownership interest or relationship other than the leases. The lease was renewed in the first quarter of fiscal year 2023 for a term of ten years through December 2032 with a renewal option for one 10-year term at prevailing market rates. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the properties. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.7 million, $ 2.6 million and 2.3 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 17.6 million and $ 19.3 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.6 million and $ 16.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.5 million and $ 18.1 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. </context> | us-gaap:OperatingLeaseRightOfUseAsset |
The Company entered into an operating lease for the occupancy of office space in a building in Cincinnati, Ohio with an entity that is wholly owned by the chief executive officer of the Company. The Company has evaluated its relationship with the related party and concluded that the related party is not a variable interest entity because the Company has no direct ownership interest or relationship other than the leases. The lease was renewed in the first quarter of fiscal year 2023 for a term of ten years through December 2032 with a renewal option for one 10-year term at prevailing market rates. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the properties. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.7 million, $ 2.6 million and 2.3 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 17.6 million and $ 19.3 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.6 million and $ 16.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.5 million and $ 18.1 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. | text | 1.6 | monetaryItemType | text: <entity> 1.6 </entity> <entity type> monetaryItemType </entity type> <context> The Company entered into an operating lease for the occupancy of office space in a building in Cincinnati, Ohio with an entity that is wholly owned by the chief executive officer of the Company. The Company has evaluated its relationship with the related party and concluded that the related party is not a variable interest entity because the Company has no direct ownership interest or relationship other than the leases. The lease was renewed in the first quarter of fiscal year 2023 for a term of ten years through December 2032 with a renewal option for one 10-year term at prevailing market rates. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the properties. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.7 million, $ 2.6 million and 2.3 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 17.6 million and $ 19.3 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.6 million and $ 16.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.5 million and $ 18.1 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. </context> | us-gaap:OperatingLeaseLiabilityCurrent |
The Company entered into an operating lease for the occupancy of office space in a building in Cincinnati, Ohio with an entity that is wholly owned by the chief executive officer of the Company. The Company has evaluated its relationship with the related party and concluded that the related party is not a variable interest entity because the Company has no direct ownership interest or relationship other than the leases. The lease was renewed in the first quarter of fiscal year 2023 for a term of ten years through December 2032 with a renewal option for one 10-year term at prevailing market rates. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the properties. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.7 million, $ 2.6 million and 2.3 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 17.6 million and $ 19.3 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.6 million and $ 16.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.5 million and $ 18.1 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. | text | 16.5 | monetaryItemType | text: <entity> 16.5 </entity> <entity type> monetaryItemType </entity type> <context> The Company entered into an operating lease for the occupancy of office space in a building in Cincinnati, Ohio with an entity that is wholly owned by the chief executive officer of the Company. The Company has evaluated its relationship with the related party and concluded that the related party is not a variable interest entity because the Company has no direct ownership interest or relationship other than the leases. The lease was renewed in the first quarter of fiscal year 2023 for a term of ten years through December 2032 with a renewal option for one 10-year term at prevailing market rates. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the properties. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.7 million, $ 2.6 million and 2.3 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 17.6 million and $ 19.3 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.6 million and $ 16.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.5 million and $ 18.1 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. </context> | us-gaap:OperatingLeaseLiabilityNoncurrent |
The Company entered into an operating lease for the occupancy of office space in a building in Cincinnati, Ohio with an entity that is wholly owned by the chief executive officer of the Company. The Company has evaluated its relationship with the related party and concluded that the related party is not a variable interest entity because the Company has no direct ownership interest or relationship other than the leases. The lease was renewed in the first quarter of fiscal year 2023 for a term of ten years through December 2032 with a renewal option for one 10-year term at prevailing market rates. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the properties. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.7 million, $ 2.6 million and 2.3 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 17.6 million and $ 19.3 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.6 million and $ 16.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.5 million and $ 18.1 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. | text | 1.5 | monetaryItemType | text: <entity> 1.5 </entity> <entity type> monetaryItemType </entity type> <context> The Company entered into an operating lease for the occupancy of office space in a building in Cincinnati, Ohio with an entity that is wholly owned by the chief executive officer of the Company. The Company has evaluated its relationship with the related party and concluded that the related party is not a variable interest entity because the Company has no direct ownership interest or relationship other than the leases. The lease was renewed in the first quarter of fiscal year 2023 for a term of ten years through December 2032 with a renewal option for one 10-year term at prevailing market rates. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the properties. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.7 million, $ 2.6 million and 2.3 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 17.6 million and $ 19.3 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.6 million and $ 16.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.5 million and $ 18.1 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. </context> | us-gaap:OperatingLeaseLiabilityCurrent |
The Company entered into an operating lease for the occupancy of office space in a building in Cincinnati, Ohio with an entity that is wholly owned by the chief executive officer of the Company. The Company has evaluated its relationship with the related party and concluded that the related party is not a variable interest entity because the Company has no direct ownership interest or relationship other than the leases. The lease was renewed in the first quarter of fiscal year 2023 for a term of ten years through December 2032 with a renewal option for one 10-year term at prevailing market rates. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the properties. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.7 million, $ 2.6 million and 2.3 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 17.6 million and $ 19.3 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.6 million and $ 16.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.5 million and $ 18.1 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. | text | 18.1 | monetaryItemType | text: <entity> 18.1 </entity> <entity type> monetaryItemType </entity type> <context> The Company entered into an operating lease for the occupancy of office space in a building in Cincinnati, Ohio with an entity that is wholly owned by the chief executive officer of the Company. The Company has evaluated its relationship with the related party and concluded that the related party is not a variable interest entity because the Company has no direct ownership interest or relationship other than the leases. The lease was renewed in the first quarter of fiscal year 2023 for a term of ten years through December 2032 with a renewal option for one 10-year term at prevailing market rates. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the properties. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.7 million, $ 2.6 million and 2.3 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 17.6 million and $ 19.3 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.6 million and $ 16.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.5 million and $ 18.1 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. </context> | us-gaap:OperatingLeaseLiabilityNoncurrent |
In 2018, Medpace, Inc. entered into a multi-year lease agreement governing future occupancy of additional office space in Cincinnati, Ohio with an entity that is wholly owned by the Company’s chief executive officer and certain members of his immediate family. The Company began to occupy the premises in the second quarter of fiscal year 2020. The lease expires in 2040 and the Company has two 10 -year options to extend the term of the lease. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 5.7 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 50.2 million and $ 51.9 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.5 million and $ 62.0 million, respectively. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.3 million and $ 63.5 million, respectively and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. | text | 50.2 | monetaryItemType | text: <entity> 50.2 </entity> <entity type> monetaryItemType </entity type> <context> In 2018, Medpace, Inc. entered into a multi-year lease agreement governing future occupancy of additional office space in Cincinnati, Ohio with an entity that is wholly owned by the Company’s chief executive officer and certain members of his immediate family. The Company began to occupy the premises in the second quarter of fiscal year 2020. The lease expires in 2040 and the Company has two 10 -year options to extend the term of the lease. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 5.7 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 50.2 million and $ 51.9 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.5 million and $ 62.0 million, respectively. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.3 million and $ 63.5 million, respectively and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. </context> | us-gaap:OperatingLeaseRightOfUseAsset |
In 2018, Medpace, Inc. entered into a multi-year lease agreement governing future occupancy of additional office space in Cincinnati, Ohio with an entity that is wholly owned by the Company’s chief executive officer and certain members of his immediate family. The Company began to occupy the premises in the second quarter of fiscal year 2020. The lease expires in 2040 and the Company has two 10 -year options to extend the term of the lease. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 5.7 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 50.2 million and $ 51.9 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.5 million and $ 62.0 million, respectively. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.3 million and $ 63.5 million, respectively and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. | text | 51.9 | monetaryItemType | text: <entity> 51.9 </entity> <entity type> monetaryItemType </entity type> <context> In 2018, Medpace, Inc. entered into a multi-year lease agreement governing future occupancy of additional office space in Cincinnati, Ohio with an entity that is wholly owned by the Company’s chief executive officer and certain members of his immediate family. The Company began to occupy the premises in the second quarter of fiscal year 2020. The lease expires in 2040 and the Company has two 10 -year options to extend the term of the lease. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 5.7 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 50.2 million and $ 51.9 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.5 million and $ 62.0 million, respectively. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.3 million and $ 63.5 million, respectively and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. </context> | us-gaap:OperatingLeaseRightOfUseAsset |
In 2018, Medpace, Inc. entered into a multi-year lease agreement governing future occupancy of additional office space in Cincinnati, Ohio with an entity that is wholly owned by the Company’s chief executive officer and certain members of his immediate family. The Company began to occupy the premises in the second quarter of fiscal year 2020. The lease expires in 2040 and the Company has two 10 -year options to extend the term of the lease. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 5.7 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 50.2 million and $ 51.9 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.5 million and $ 62.0 million, respectively. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.3 million and $ 63.5 million, respectively and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. | text | 1.5 | monetaryItemType | text: <entity> 1.5 </entity> <entity type> monetaryItemType </entity type> <context> In 2018, Medpace, Inc. entered into a multi-year lease agreement governing future occupancy of additional office space in Cincinnati, Ohio with an entity that is wholly owned by the Company’s chief executive officer and certain members of his immediate family. The Company began to occupy the premises in the second quarter of fiscal year 2020. The lease expires in 2040 and the Company has two 10 -year options to extend the term of the lease. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 5.7 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 50.2 million and $ 51.9 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.5 million and $ 62.0 million, respectively. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.3 million and $ 63.5 million, respectively and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. </context> | us-gaap:OperatingLeaseLiabilityCurrent |
In 2018, Medpace, Inc. entered into a multi-year lease agreement governing future occupancy of additional office space in Cincinnati, Ohio with an entity that is wholly owned by the Company’s chief executive officer and certain members of his immediate family. The Company began to occupy the premises in the second quarter of fiscal year 2020. The lease expires in 2040 and the Company has two 10 -year options to extend the term of the lease. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 5.7 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 50.2 million and $ 51.9 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.5 million and $ 62.0 million, respectively. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.3 million and $ 63.5 million, respectively and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. | text | 62.0 | monetaryItemType | text: <entity> 62.0 </entity> <entity type> monetaryItemType </entity type> <context> In 2018, Medpace, Inc. entered into a multi-year lease agreement governing future occupancy of additional office space in Cincinnati, Ohio with an entity that is wholly owned by the Company’s chief executive officer and certain members of his immediate family. The Company began to occupy the premises in the second quarter of fiscal year 2020. The lease expires in 2040 and the Company has two 10 -year options to extend the term of the lease. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 5.7 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 50.2 million and $ 51.9 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.5 million and $ 62.0 million, respectively. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.3 million and $ 63.5 million, respectively and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. </context> | us-gaap:OperatingLeaseLiabilityNoncurrent |
In 2018, Medpace, Inc. entered into a multi-year lease agreement governing future occupancy of additional office space in Cincinnati, Ohio with an entity that is wholly owned by the Company’s chief executive officer and certain members of his immediate family. The Company began to occupy the premises in the second quarter of fiscal year 2020. The lease expires in 2040 and the Company has two 10 -year options to extend the term of the lease. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 5.7 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 50.2 million and $ 51.9 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.5 million and $ 62.0 million, respectively. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.3 million and $ 63.5 million, respectively and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. | text | 1.3 | monetaryItemType | text: <entity> 1.3 </entity> <entity type> monetaryItemType </entity type> <context> In 2018, Medpace, Inc. entered into a multi-year lease agreement governing future occupancy of additional office space in Cincinnati, Ohio with an entity that is wholly owned by the Company’s chief executive officer and certain members of his immediate family. The Company began to occupy the premises in the second quarter of fiscal year 2020. The lease expires in 2040 and the Company has two 10 -year options to extend the term of the lease. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 5.7 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 50.2 million and $ 51.9 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.5 million and $ 62.0 million, respectively. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.3 million and $ 63.5 million, respectively and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. </context> | us-gaap:OperatingLeaseLiabilityCurrent |
In 2018, Medpace, Inc. entered into a multi-year lease agreement governing future occupancy of additional office space in Cincinnati, Ohio with an entity that is wholly owned by the Company’s chief executive officer and certain members of his immediate family. The Company began to occupy the premises in the second quarter of fiscal year 2020. The lease expires in 2040 and the Company has two 10 -year options to extend the term of the lease. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 5.7 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 50.2 million and $ 51.9 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.5 million and $ 62.0 million, respectively. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.3 million and $ 63.5 million, respectively and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. | text | 63.5 | monetaryItemType | text: <entity> 63.5 </entity> <entity type> monetaryItemType </entity type> <context> In 2018, Medpace, Inc. entered into a multi-year lease agreement governing future occupancy of additional office space in Cincinnati, Ohio with an entity that is wholly owned by the Company’s chief executive officer and certain members of his immediate family. The Company began to occupy the premises in the second quarter of fiscal year 2020. The lease expires in 2040 and the Company has two 10 -year options to extend the term of the lease. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 5.7 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 50.2 million and $ 51.9 million in the consolidated balance sheets, respectively. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 1.5 million and $ 62.0 million, respectively. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 1.3 million and $ 63.5 million, respectively and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. </context> | us-gaap:OperatingLeaseLiabilityNoncurrent |
10 -year option to extend the lease term. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.5 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 6.4 million and $ 8.5 million, respectively, in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 2.2 million and $ 4.2 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 2.1 million and $ 6.4 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. | text | 6.4 | monetaryItemType | text: <entity> 6.4 </entity> <entity type> monetaryItemType </entity type> <context> 10 -year option to extend the lease term. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.5 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 6.4 million and $ 8.5 million, respectively, in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 2.2 million and $ 4.2 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 2.1 million and $ 6.4 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. </context> | us-gaap:OperatingLeaseRightOfUseAsset |
10 -year option to extend the lease term. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.5 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 6.4 million and $ 8.5 million, respectively, in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 2.2 million and $ 4.2 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 2.1 million and $ 6.4 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. | text | 8.5 | monetaryItemType | text: <entity> 8.5 </entity> <entity type> monetaryItemType </entity type> <context> 10 -year option to extend the lease term. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.5 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 6.4 million and $ 8.5 million, respectively, in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 2.2 million and $ 4.2 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 2.1 million and $ 6.4 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. </context> | us-gaap:OperatingLeaseRightOfUseAsset |
10 -year option to extend the lease term. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.5 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 6.4 million and $ 8.5 million, respectively, in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 2.2 million and $ 4.2 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 2.1 million and $ 6.4 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. | text | 2.2 | monetaryItemType | text: <entity> 2.2 </entity> <entity type> monetaryItemType </entity type> <context> 10 -year option to extend the lease term. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.5 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 6.4 million and $ 8.5 million, respectively, in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 2.2 million and $ 4.2 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 2.1 million and $ 6.4 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. </context> | us-gaap:OperatingLeaseLiabilityCurrent |
10 -year option to extend the lease term. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.5 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 6.4 million and $ 8.5 million, respectively, in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 2.2 million and $ 4.2 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 2.1 million and $ 6.4 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. | text | 4.2 | monetaryItemType | text: <entity> 4.2 </entity> <entity type> monetaryItemType </entity type> <context> 10 -year option to extend the lease term. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.5 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 6.4 million and $ 8.5 million, respectively, in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 2.2 million and $ 4.2 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 2.1 million and $ 6.4 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. </context> | us-gaap:OperatingLeaseLiabilityNoncurrent |
10 -year option to extend the lease term. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.5 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 6.4 million and $ 8.5 million, respectively, in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 2.2 million and $ 4.2 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 2.1 million and $ 6.4 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. | text | 2.1 | monetaryItemType | text: <entity> 2.1 </entity> <entity type> monetaryItemType </entity type> <context> 10 -year option to extend the lease term. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.5 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 6.4 million and $ 8.5 million, respectively, in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 2.2 million and $ 4.2 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 2.1 million and $ 6.4 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. </context> | us-gaap:OperatingLeaseLiabilityCurrent |
10 -year option to extend the lease term. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.5 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 6.4 million and $ 8.5 million, respectively, in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 2.2 million and $ 4.2 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 2.1 million and $ 6.4 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. | text | 6.4 | monetaryItemType | text: <entity> 6.4 </entity> <entity type> monetaryItemType </entity type> <context> 10 -year option to extend the lease term. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.5 million, respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 6.4 million and $ 8.5 million, respectively, in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 2.2 million and $ 4.2 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 2.1 million and $ 6.4 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. </context> | us-gaap:OperatingLeaseLiabilityNoncurrent |
The Company entered into a multi-year lease agreement governing the occupancy of office space in a building in Cincinnati, Ohio with an entity that is wholly owned by the Company's chief executive officer and certain members of his immediate family. The Company assumed occupancy in 2012 and the lease expires in 2027 with the Company having one 10 -year option to extend the lease term. In the first quarter of 2024, the Company reduced the lease term in connection with a plan to replace the leased office beginning in early 2025. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.9 million, $ 1.1 million and $ 1.1 million | text | 2.9 | monetaryItemType | text: <entity> 2.9 </entity> <entity type> monetaryItemType </entity type> <context> The Company entered into a multi-year lease agreement governing the occupancy of office space in a building in Cincinnati, Ohio with an entity that is wholly owned by the Company's chief executive officer and certain members of his immediate family. The Company assumed occupancy in 2012 and the lease expires in 2027 with the Company having one 10 -year option to extend the lease term. In the first quarter of 2024, the Company reduced the lease term in connection with a plan to replace the leased office beginning in early 2025. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.9 million, $ 1.1 million and $ 1.1 million </context> | us-gaap:OperatingLeaseCost |
The Company entered into a multi-year lease agreement governing the occupancy of office space in a building in Cincinnati, Ohio with an entity that is wholly owned by the Company's chief executive officer and certain members of his immediate family. The Company assumed occupancy in 2012 and the lease expires in 2027 with the Company having one 10 -year option to extend the lease term. In the first quarter of 2024, the Company reduced the lease term in connection with a plan to replace the leased office beginning in early 2025. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.9 million, $ 1.1 million and $ 1.1 million | text | 1.1 | monetaryItemType | text: <entity> 1.1 </entity> <entity type> monetaryItemType </entity type> <context> The Company entered into a multi-year lease agreement governing the occupancy of office space in a building in Cincinnati, Ohio with an entity that is wholly owned by the Company's chief executive officer and certain members of his immediate family. The Company assumed occupancy in 2012 and the lease expires in 2027 with the Company having one 10 -year option to extend the lease term. In the first quarter of 2024, the Company reduced the lease term in connection with a plan to replace the leased office beginning in early 2025. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. The Company has determined that the lease is an operating lease. Operating lease cost recognized for the years ended December 31, 2024, 2023 and 2022 was $ 2.9 million, $ 1.1 million and $ 1.1 million </context> | us-gaap:OperatingLeaseCost |
respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 0.7 million and $ 3.4 million, respectively, in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 0.9 million and $ 1.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 0.9 million and $ 2.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. | text | 0.7 | monetaryItemType | text: <entity> 0.7 </entity> <entity type> monetaryItemType </entity type> <context> respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 0.7 million and $ 3.4 million, respectively, in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 0.9 million and $ 1.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 0.9 million and $ 2.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. </context> | us-gaap:OperatingLeaseRightOfUseAsset |
respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 0.7 million and $ 3.4 million, respectively, in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 0.9 million and $ 1.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 0.9 million and $ 2.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. | text | 3.4 | monetaryItemType | text: <entity> 3.4 </entity> <entity type> monetaryItemType </entity type> <context> respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 0.7 million and $ 3.4 million, respectively, in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 0.9 million and $ 1.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 0.9 million and $ 2.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. </context> | us-gaap:OperatingLeaseRightOfUseAsset |
respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 0.7 million and $ 3.4 million, respectively, in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 0.9 million and $ 1.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 0.9 million and $ 2.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. | text | 0.9 | monetaryItemType | text: <entity> 0.9 </entity> <entity type> monetaryItemType </entity type> <context> respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 0.7 million and $ 3.4 million, respectively, in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 0.9 million and $ 1.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 0.9 million and $ 2.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. </context> | us-gaap:OperatingLeaseLiabilityCurrent |
respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 0.7 million and $ 3.4 million, respectively, in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 0.9 million and $ 1.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 0.9 million and $ 2.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. | text | 1.5 | monetaryItemType | text: <entity> 1.5 </entity> <entity type> monetaryItemType </entity type> <context> respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 0.7 million and $ 3.4 million, respectively, in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 0.9 million and $ 1.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 0.9 million and $ 2.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. </context> | us-gaap:OperatingLeaseLiabilityNoncurrent |
respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 0.7 million and $ 3.4 million, respectively, in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 0.9 million and $ 1.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 0.9 million and $ 2.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. | text | 2.5 | monetaryItemType | text: <entity> 2.5 </entity> <entity type> monetaryItemType </entity type> <context> respectively. The operating lease cost was allocated between Total direct costs and Selling, general and administrative in the consolidated statements of operations. The Operating lease right-of-use assets at December 31, 2024 and 2023 were $ 0.7 million and $ 3.4 million, respectively, in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2024 were $ 0.9 million and $ 1.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. The current and long-term portions of the lease liabilities at December 31, 2023 were $ 0.9 million and $ 2.5 million, respectively, and were recognized in Other current liabilities and Operating lease liabilities in the consolidated balance sheets. </context> | us-gaap:OperatingLeaseLiabilityNoncurrent |
The Company incurs expenses for travel services for company executives provided by private aviation charter companies which is a company controlled by the chief executive officer of the Company (each a “private aviation charter”). The Company may contract directly with the private aviation charter for the use of its aircraft or indirectly through a third party aircraft management and jet charter company (the “Aircraft Management Company”). The travel services provided are primarily for business purposes, with certain personal travel paid for as part of the executives’ compensation arrangements. The Aircraft Management Company also makes the private aviation charter aircraft available to third parties. The Company incurred travel expenses of $ 1.9 million, $ 2.0 million and $ 2.3 million during the years ended December 31, 2024, 2023 and 2022, respectively. These travel expenses are recorded in Selling, general and administrative in the Company’s consolidated statements of operations. As of December 31, 2024 and 2023, the Company had Accounts payable to the Aircraft Management Company of $ 0.2 million and $ 0.4 million, respectively, in the consolidated balance sheets. | text | 1.9 | monetaryItemType | text: <entity> 1.9 </entity> <entity type> monetaryItemType </entity type> <context> The Company incurs expenses for travel services for company executives provided by private aviation charter companies which is a company controlled by the chief executive officer of the Company (each a “private aviation charter”). The Company may contract directly with the private aviation charter for the use of its aircraft or indirectly through a third party aircraft management and jet charter company (the “Aircraft Management Company”). The travel services provided are primarily for business purposes, with certain personal travel paid for as part of the executives’ compensation arrangements. The Aircraft Management Company also makes the private aviation charter aircraft available to third parties. The Company incurred travel expenses of $ 1.9 million, $ 2.0 million and $ 2.3 million during the years ended December 31, 2024, 2023 and 2022, respectively. These travel expenses are recorded in Selling, general and administrative in the Company’s consolidated statements of operations. As of December 31, 2024 and 2023, the Company had Accounts payable to the Aircraft Management Company of $ 0.2 million and $ 0.4 million, respectively, in the consolidated balance sheets. </context> | us-gaap:TravelAndEntertainmentExpense |
The Company incurs expenses for travel services for company executives provided by private aviation charter companies which is a company controlled by the chief executive officer of the Company (each a “private aviation charter”). The Company may contract directly with the private aviation charter for the use of its aircraft or indirectly through a third party aircraft management and jet charter company (the “Aircraft Management Company”). The travel services provided are primarily for business purposes, with certain personal travel paid for as part of the executives’ compensation arrangements. The Aircraft Management Company also makes the private aviation charter aircraft available to third parties. The Company incurred travel expenses of $ 1.9 million, $ 2.0 million and $ 2.3 million during the years ended December 31, 2024, 2023 and 2022, respectively. These travel expenses are recorded in Selling, general and administrative in the Company’s consolidated statements of operations. As of December 31, 2024 and 2023, the Company had Accounts payable to the Aircraft Management Company of $ 0.2 million and $ 0.4 million, respectively, in the consolidated balance sheets. | text | 2.0 | monetaryItemType | text: <entity> 2.0 </entity> <entity type> monetaryItemType </entity type> <context> The Company incurs expenses for travel services for company executives provided by private aviation charter companies which is a company controlled by the chief executive officer of the Company (each a “private aviation charter”). The Company may contract directly with the private aviation charter for the use of its aircraft or indirectly through a third party aircraft management and jet charter company (the “Aircraft Management Company”). The travel services provided are primarily for business purposes, with certain personal travel paid for as part of the executives’ compensation arrangements. The Aircraft Management Company also makes the private aviation charter aircraft available to third parties. The Company incurred travel expenses of $ 1.9 million, $ 2.0 million and $ 2.3 million during the years ended December 31, 2024, 2023 and 2022, respectively. These travel expenses are recorded in Selling, general and administrative in the Company’s consolidated statements of operations. As of December 31, 2024 and 2023, the Company had Accounts payable to the Aircraft Management Company of $ 0.2 million and $ 0.4 million, respectively, in the consolidated balance sheets. </context> | us-gaap:TravelAndEntertainmentExpense |
The Company incurs expenses for travel services for company executives provided by private aviation charter companies which is a company controlled by the chief executive officer of the Company (each a “private aviation charter”). The Company may contract directly with the private aviation charter for the use of its aircraft or indirectly through a third party aircraft management and jet charter company (the “Aircraft Management Company”). The travel services provided are primarily for business purposes, with certain personal travel paid for as part of the executives’ compensation arrangements. The Aircraft Management Company also makes the private aviation charter aircraft available to third parties. The Company incurred travel expenses of $ 1.9 million, $ 2.0 million and $ 2.3 million during the years ended December 31, 2024, 2023 and 2022, respectively. These travel expenses are recorded in Selling, general and administrative in the Company’s consolidated statements of operations. As of December 31, 2024 and 2023, the Company had Accounts payable to the Aircraft Management Company of $ 0.2 million and $ 0.4 million, respectively, in the consolidated balance sheets. | text | 2.3 | monetaryItemType | text: <entity> 2.3 </entity> <entity type> monetaryItemType </entity type> <context> The Company incurs expenses for travel services for company executives provided by private aviation charter companies which is a company controlled by the chief executive officer of the Company (each a “private aviation charter”). The Company may contract directly with the private aviation charter for the use of its aircraft or indirectly through a third party aircraft management and jet charter company (the “Aircraft Management Company”). The travel services provided are primarily for business purposes, with certain personal travel paid for as part of the executives’ compensation arrangements. The Aircraft Management Company also makes the private aviation charter aircraft available to third parties. The Company incurred travel expenses of $ 1.9 million, $ 2.0 million and $ 2.3 million during the years ended December 31, 2024, 2023 and 2022, respectively. These travel expenses are recorded in Selling, general and administrative in the Company’s consolidated statements of operations. As of December 31, 2024 and 2023, the Company had Accounts payable to the Aircraft Management Company of $ 0.2 million and $ 0.4 million, respectively, in the consolidated balance sheets. </context> | us-gaap:TravelAndEntertainmentExpense |
The Company incurs expenses for travel services for company executives provided by private aviation charter companies which is a company controlled by the chief executive officer of the Company (each a “private aviation charter”). The Company may contract directly with the private aviation charter for the use of its aircraft or indirectly through a third party aircraft management and jet charter company (the “Aircraft Management Company”). The travel services provided are primarily for business purposes, with certain personal travel paid for as part of the executives’ compensation arrangements. The Aircraft Management Company also makes the private aviation charter aircraft available to third parties. The Company incurred travel expenses of $ 1.9 million, $ 2.0 million and $ 2.3 million during the years ended December 31, 2024, 2023 and 2022, respectively. These travel expenses are recorded in Selling, general and administrative in the Company’s consolidated statements of operations. As of December 31, 2024 and 2023, the Company had Accounts payable to the Aircraft Management Company of $ 0.2 million and $ 0.4 million, respectively, in the consolidated balance sheets. | text | 0.2 | monetaryItemType | text: <entity> 0.2 </entity> <entity type> monetaryItemType </entity type> <context> The Company incurs expenses for travel services for company executives provided by private aviation charter companies which is a company controlled by the chief executive officer of the Company (each a “private aviation charter”). The Company may contract directly with the private aviation charter for the use of its aircraft or indirectly through a third party aircraft management and jet charter company (the “Aircraft Management Company”). The travel services provided are primarily for business purposes, with certain personal travel paid for as part of the executives’ compensation arrangements. The Aircraft Management Company also makes the private aviation charter aircraft available to third parties. The Company incurred travel expenses of $ 1.9 million, $ 2.0 million and $ 2.3 million during the years ended December 31, 2024, 2023 and 2022, respectively. These travel expenses are recorded in Selling, general and administrative in the Company’s consolidated statements of operations. As of December 31, 2024 and 2023, the Company had Accounts payable to the Aircraft Management Company of $ 0.2 million and $ 0.4 million, respectively, in the consolidated balance sheets. </context> | us-gaap:AccountsPayableCurrent |
The Company incurs expenses for travel services for company executives provided by private aviation charter companies which is a company controlled by the chief executive officer of the Company (each a “private aviation charter”). The Company may contract directly with the private aviation charter for the use of its aircraft or indirectly through a third party aircraft management and jet charter company (the “Aircraft Management Company”). The travel services provided are primarily for business purposes, with certain personal travel paid for as part of the executives’ compensation arrangements. The Aircraft Management Company also makes the private aviation charter aircraft available to third parties. The Company incurred travel expenses of $ 1.9 million, $ 2.0 million and $ 2.3 million during the years ended December 31, 2024, 2023 and 2022, respectively. These travel expenses are recorded in Selling, general and administrative in the Company’s consolidated statements of operations. As of December 31, 2024 and 2023, the Company had Accounts payable to the Aircraft Management Company of $ 0.2 million and $ 0.4 million, respectively, in the consolidated balance sheets. | text | 0.4 | monetaryItemType | text: <entity> 0.4 </entity> <entity type> monetaryItemType </entity type> <context> The Company incurs expenses for travel services for company executives provided by private aviation charter companies which is a company controlled by the chief executive officer of the Company (each a “private aviation charter”). The Company may contract directly with the private aviation charter for the use of its aircraft or indirectly through a third party aircraft management and jet charter company (the “Aircraft Management Company”). The travel services provided are primarily for business purposes, with certain personal travel paid for as part of the executives’ compensation arrangements. The Aircraft Management Company also makes the private aviation charter aircraft available to third parties. The Company incurred travel expenses of $ 1.9 million, $ 2.0 million and $ 2.3 million during the years ended December 31, 2024, 2023 and 2022, respectively. These travel expenses are recorded in Selling, general and administrative in the Company’s consolidated statements of operations. As of December 31, 2024 and 2023, the Company had Accounts payable to the Aircraft Management Company of $ 0.2 million and $ 0.4 million, respectively, in the consolidated balance sheets. </context> | us-gaap:AccountsPayableCurrent |
The Company’s assets are held by, and all of its operations are conducted through, directly or indirectly, Agree Limited Partnership (the “Operating Partnership”), of which Agree Realty Corporation is the sole general partner and in which it held a 99.7 % and 99.6 % common equity interest as of December 31, 2023 and 2022, respectively. There is a one-for-one relationship between the limited partnership interests in the Operating Partnership (“Operating Partnership Common Units”) owned by the Company and shares of Company common stock outstanding. The Company also owns 100 % of the Series A preferred equity interest in the Operating Partnership. This preferred equity interest corresponds on a one-for-one basis to the Company’s Series A Preferred Stock (Refer to Note 6 - Common and Preferred Stock ), providing income and distributions to the Company equal to the dividends payable on that stock. | text | 99.7 | percentItemType | text: <entity> 99.7 </entity> <entity type> percentItemType </entity type> <context> The Company’s assets are held by, and all of its operations are conducted through, directly or indirectly, Agree Limited Partnership (the “Operating Partnership”), of which Agree Realty Corporation is the sole general partner and in which it held a 99.7 % and 99.6 % common equity interest as of December 31, 2023 and 2022, respectively. There is a one-for-one relationship between the limited partnership interests in the Operating Partnership (“Operating Partnership Common Units”) owned by the Company and shares of Company common stock outstanding. The Company also owns 100 % of the Series A preferred equity interest in the Operating Partnership. This preferred equity interest corresponds on a one-for-one basis to the Company’s Series A Preferred Stock (Refer to Note 6 - Common and Preferred Stock ), providing income and distributions to the Company equal to the dividends payable on that stock. </context> | us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest |
The Company’s assets are held by, and all of its operations are conducted through, directly or indirectly, Agree Limited Partnership (the “Operating Partnership”), of which Agree Realty Corporation is the sole general partner and in which it held a 99.7 % and 99.6 % common equity interest as of December 31, 2023 and 2022, respectively. There is a one-for-one relationship between the limited partnership interests in the Operating Partnership (“Operating Partnership Common Units”) owned by the Company and shares of Company common stock outstanding. The Company also owns 100 % of the Series A preferred equity interest in the Operating Partnership. This preferred equity interest corresponds on a one-for-one basis to the Company’s Series A Preferred Stock (Refer to Note 6 - Common and Preferred Stock ), providing income and distributions to the Company equal to the dividends payable on that stock. | text | 99.6 | percentItemType | text: <entity> 99.6 </entity> <entity type> percentItemType </entity type> <context> The Company’s assets are held by, and all of its operations are conducted through, directly or indirectly, Agree Limited Partnership (the “Operating Partnership”), of which Agree Realty Corporation is the sole general partner and in which it held a 99.7 % and 99.6 % common equity interest as of December 31, 2023 and 2022, respectively. There is a one-for-one relationship between the limited partnership interests in the Operating Partnership (“Operating Partnership Common Units”) owned by the Company and shares of Company common stock outstanding. The Company also owns 100 % of the Series A preferred equity interest in the Operating Partnership. This preferred equity interest corresponds on a one-for-one basis to the Company’s Series A Preferred Stock (Refer to Note 6 - Common and Preferred Stock ), providing income and distributions to the Company equal to the dividends payable on that stock. </context> | us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest |
The Company’s assets are held by, and all of its operations are conducted through, directly or indirectly, Agree Limited Partnership (the “Operating Partnership”), of which Agree Realty Corporation is the sole general partner and in which it held a 99.7 % and 99.6 % common equity interest as of December 31, 2023 and 2022, respectively. There is a one-for-one relationship between the limited partnership interests in the Operating Partnership (“Operating Partnership Common Units”) owned by the Company and shares of Company common stock outstanding. The Company also owns 100 % of the Series A preferred equity interest in the Operating Partnership. This preferred equity interest corresponds on a one-for-one basis to the Company’s Series A Preferred Stock (Refer to Note 6 - Common and Preferred Stock ), providing income and distributions to the Company equal to the dividends payable on that stock. | text | 100 | percentItemType | text: <entity> 100 </entity> <entity type> percentItemType </entity type> <context> The Company’s assets are held by, and all of its operations are conducted through, directly or indirectly, Agree Limited Partnership (the “Operating Partnership”), of which Agree Realty Corporation is the sole general partner and in which it held a 99.7 % and 99.6 % common equity interest as of December 31, 2023 and 2022, respectively. There is a one-for-one relationship between the limited partnership interests in the Operating Partnership (“Operating Partnership Common Units”) owned by the Company and shares of Company common stock outstanding. The Company also owns 100 % of the Series A preferred equity interest in the Operating Partnership. This preferred equity interest corresponds on a one-for-one basis to the Company’s Series A Preferred Stock (Refer to Note 6 - Common and Preferred Stock ), providing income and distributions to the Company equal to the dividends payable on that stock. </context> | us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.